<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Discov</journal-id><journal-id journal-id-type="iso-abbrev">Cell Death Discov</journal-id><journal-title-group><journal-title>Cell Death Discovery</journal-title></journal-title-group><issn pub-type="epub">2058-7716</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40188055</article-id><article-id pub-id-type="pmc">PMC11972320</article-id><article-id pub-id-type="publisher-id">2429</article-id><article-id pub-id-type="doi">10.1038/s41420-025-02429-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Qingling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yanlong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Xueqing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Meijun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xunsheng</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9919-2425</contrib-id><name><surname>Ding</surname><given-names>Jie</given-names></name><address><email>dingjiesydoc@126.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02wmsc916</institution-id><institution-id institution-id-type="GRID">grid.443382.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1804 268X</institution-id><institution>GuiZhou University Medical College, </institution></institution-wrap>Guiyang, 550025 Guizhou China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046q1bp69</institution-id><institution-id institution-id-type="GRID">grid.459540.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 4503</institution-id><institution>NHC Key Laboratory of Pulmonary Immunological Diseases, </institution><institution>Guizhou Provincial People&#x02019;s Hospital, </institution></institution-wrap>Guiyang, 550002 Guizhou China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g5b0g93</institution-id><institution-id institution-id-type="GRID">grid.417409.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0240 6969</institution-id><institution>Graduate School, </institution><institution>Zunyi Medical University, </institution></institution-wrap>Zunyi, Guizhou 563006 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046q1bp69</institution-id><institution-id institution-id-type="GRID">grid.459540.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 4503</institution-id><institution>Department of Gastrointestinal Surgery, </institution><institution>Guizhou Provincial People&#x02019;s Hospital, Guiyang, </institution></institution-wrap>550002 Guiyang, China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><elocation-id>144</elocation-id><history><date date-type="received"><day>5</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>7</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Gastric cancer, marked by its high incidence and poor prognosis, demands the urgent development of novel and effective treatment strategies, especially for patients ineligible for surgery or those who have had limited success with chemotherapy, radiotherapy and targeted therapies. Recently, antibody-drug conjugates (ADCs) have become a key area of investigation due to their high specificity and potent antitumor effects. These therapies combine monoclonal antibodies, designed to bind to tumor-specific antigens, with cytotoxic agents that selectively target and destroy malignant cells. ADCs have generated significant interest in clinical trials as a promising approach to improve both treatment efficacy and patient outcomes in gastric cancer. However, their clinical application is not without challenges and limitations that must be addressed. This review discusses the recent progress in the use of ADCs for gastric cancer treatment.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer therapy</kwd><kwd>Drug delivery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004001</institution-id><institution>Guizhou Science and Technology Department (Department of Science and Technology, Guizhou Province)</institution></institution-wrap></funding-source><award-id>[2020]1Z064</award-id><award-id>[2019]1198</award-id><principal-award-recipient><name><surname>Ding</surname><given-names>Jie</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>82360586</award-id><award-id>81302169</award-id><award-id>81360366</award-id><principal-award-recipient><name><surname>Ding</surname><given-names>Jie</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Cell Death Differentiation Association (ADMC) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Facts</title><p id="Par2">
<list list-type="bullet"><list-item><p id="Par3">Antibody-drug conjugates have gained considerable attention in research for their high selectivity and potent antitumor activity.</p></list-item><list-item><p id="Par4">Evolution of gastric cancer involves multiple mechanisms.</p></list-item><list-item><p id="Par5">Continued research and development of antibody-drug conjugates must be supported by comprehensive clinical data and accurate disease classification to ensure their effective integration into clinical practice.</p></list-item></list>
</p></sec><sec id="Sec2"><title>Questions</title><p id="Par6">
<list list-type="bullet"><list-item><p id="Par7">What molecular mechanisms drive the pathogenesis of gastric cancer?</p></list-item><list-item><p id="Par8">How do antibody-drug conjugates modulate the tumor microenvironment to exert their effects?</p></list-item><list-item><p id="Par9">What are the clinical outcomes associated with antibody-drug conjugates, and what implications do they hold for patient care?</p></list-item><list-item><p id="Par10">How can the design and optimization of antibody-drug conjugates be advanced to improve their efficacy and safety?</p></list-item></list>
</p></sec><sec id="Sec3" sec-type="introduction"><title>Introduction</title><p id="Par11">Gastric cancer (GC) ranks as the fifth most prevalent malignancy globally and is the third leading cause of cancer-related mortality [<xref ref-type="bibr" rid="CR1">1</xref>], reflecting the substantial health burden it imposes worldwide (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Over 95% of GC cases are adenocarcinomas originating from the gastric mucosal epithelium. These adenocarcinomas are categorized based on their anatomical location (cardia/proximal or non-cardia/distal) and histological subtype (diffuse or intestinal) [<xref ref-type="bibr" rid="CR2">2</xref>]. The diffuse type of GC is characterized by poorly differentiated, scattered tumor cells with irregular or absent glandular structures, along with diffuse infiltration into the gastric lining and proliferative mesenchymal connective tissue. This subtype is more commonly observed in low-risk regions and is predominantly linked to genetic mutations, indicating a significant genetic predisposition [<xref ref-type="bibr" rid="CR3">3</xref>]. In contrast, the intestinal type of GC is marked by tumor cells that exhibit variable differentiation and form tubular or glandular patterns, interspersed with scattered cup-shaped cells. It is the predominant form in high-risk areas and accounts for much of the geographic variability in GC incidence. The intestinal type is strongly associated with environmental risk factors, including Helicobacter pylori (H. pylori) infection, smoking, and high salt intake, highlighting the influence of lifestyle and dietary habits on its development (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Certain GC cases also present TP53 gene mutations, often accompanied by distinct morphological changes [<xref ref-type="bibr" rid="CR5">5</xref>]. while a significant correlation has been observed between H. pylori infection and kirsten rat sarcoma viral oncogene (KRAS) mutations in GC patients [<xref ref-type="bibr" rid="CR6">6</xref>]. These mutations may serve as important diagnostic markers, guiding the treatment of various malignancies.<fig id="Fig1"><label>Fig. 1</label><caption><title>Global maps present the seven-tier Age-Standardized Rate per 100000.</title><p>The sizes of the respective populations are included in the legend. Source: United Nations Procurement Division/United Nations Development Program. ASR indicates Age-Standardized Rate. Source: GLOBOCAN 2022.</p></caption><graphic xlink:href="41420_2025_2429_Fig1_HTML" id="d33e308"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><title>Evolution of GC and its causes.</title><p>The progression from common gastric lesions to GC occurs through four stages: Stage 1: Chronic non-atrophic gastritis. Stage 2: Chronic atrophic gastritis, a precancerous lesion that warrants attention. In cases of Helicobacter pylori infection, eradication should be initiated without delay. Stage 3: Intestinal metaplasia, a further advancement in precancerous lesions. If left untreated, some of these lesions may progress to early GC. Stage 4: GC, the final malignant stage, typically presents with no distinct symptoms or signs in its early phases. The etiology of GC is multifactorial, including lifestyle, dietary habits, infectious agents, genetic predispositions, and other contributing factors.</p></caption><graphic xlink:href="41420_2025_2429_Fig2_HTML" id="d33e316"/></fig></p><p id="Par12">Surgical interventions are effective in managing early-stage GC, while advanced-stage cases necessitate a multifaceted approach, which may include surgery, perioperative chemotherapy, radiotherapy, targeted therapy, and immunotherapy [<xref ref-type="bibr" rid="CR1">1</xref>]. The role of biologics in first-line treatment for advanced GC is currently under investigation, particularly in relation to trastuzumab [<xref ref-type="bibr" rid="CR1">1</xref>]. Treatment strategies are tailored to the patient&#x02019;s specific pathology and clinical stage. Although treatment options for GC have advanced significantly in recent years, the majority of patients are diagnosed at later stages, restricting curative treatment possibilities. This is largely attributed to the high incidence and asymptomatic nature of the disease [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Consequently, a deeper understanding of the molecular mechanisms underlying GC pathogenesis and metastasis is essential to identify novel therapeutic targets that could enhance patient outcomes.</p><p id="Par13">For patients with intermediate and advanced GC, the integration of targeted therapies based on molecular targets marks a significant advancement in the precision surgical treatment of GC [<xref ref-type="bibr" rid="CR9">9</xref>]. Targeted therapy has become a key innovation in cancer management, operating on the principle of developing drugs that intervene at the molecular level within cells. These therapeutics are specifically designed to interact with defined molecular sites within tumor cells that drive oncogenesis, such as particular proteins or gene fragments. Upon administration, these drugs selectively bind to their targets, leading to the targeted destruction of tumor cells while sparing surrounding healthy tissues [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Despite their effectiveness, targeted therapies have limitations, as patients may experience adverse effects and develop resistance. Cancer treatment resistance is typically classified into primary and secondary types. Primary resistance refers to the absence of any initial therapeutic response, signifying that the treatment is ineffective from the start. Secondary or acquired resistance occurs when an initially responsive treatment loses its efficacy over time, allowing tumor progression to resume [<xref ref-type="bibr" rid="CR12">12</xref>]. Thus, the identification of novel therapeutic targets and approaches remains essential, not only to address treatment-resistant tumors but also to counteract drug resistance, ultimately enhancing patient outcomes. Such efforts are critical to the continued advancement of cancer treatment [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par14">Recent advancements in monoclonal antibody technology, coupled with innovations in payloads, linkers, and tumor-specific targets, have led to the emergence of antibody-drug conjugates (ADCs) as a novel class of therapeutic agents [<xref ref-type="bibr" rid="CR14">14</xref>]. ADCs have become a focal point in cancer drug development, offering a new strategy for treatment [<xref ref-type="bibr" rid="CR15">15</xref>]. These conjugates integrate antibodies that selectively bind to antigens on cancer cells with cytotoxic drugs capable of inducing cell death. This targeted approach enables the precise delivery of the cytotoxic agent to cancer cells, minimizing collateral damage to healthy tissue [<xref ref-type="bibr" rid="CR16">16</xref>]. Often referred to as &#x0201c;bio-missiles&#x0201d; or &#x0201c;magic bullets,&#x0201d; ADCs are celebrated for their precision in drug delivery. The concept of &#x0201c;magic bullets,&#x0201d; first introduced by German immunologist Paul Ehrlich, envisioned monoclonal antibodies (mAbs) capable of selectively targeting pathogens without harming the host organism. The progression of ADC development has been greatly enhanced by advances in chemical conjugation techniques and the production of humanized mAbs, facilitating their approval for clinical trials [<xref ref-type="bibr" rid="CR17">17</xref>]. As of the end of 2022, 15 ADCs have received regulatory approval for clinical use worldwide (Table <xref rid="Tab1" ref-type="table">1</xref>), marking a significant milestone in cancer therapeutics.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Globally approved and marketed antibody-drug conjugates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trade name</th><th>Name of drug</th><th>Research and development organization</th><th>Date of first listing</th><th>Therapeutic target</th><th>Type of cancer</th></tr></thead><tbody><tr><td>Mylotarg</td><td>Gemtuzumab Ozogamicin</td><td>Pfizer, American pharmaceutical company</td><td><p>2000/05/17 (first authorized)</p><p>2010/06 (withdrawn from the market)</p><p>2017/09/01 (reauthorized)</p></td><td>CD33</td><td>Leukaemia</td></tr><tr><td>Adcetris</td><td>Brentuximab Vedotin</td><td>SEAGEN/Takeda</td><td>2011/08/19</td><td>CD30</td><td>Hodgkin&#x02019;s lymphoma, Mesenchymal large cell lymphoma</td></tr><tr><td>Kadcyla</td><td>Trastuzumab Emtansine</td><td>F. Hoffmann-La Roche Ltd</td><td>2013/02/22</td><td>HER2</td><td>HER2-positive breast cancer</td></tr><tr><td>Besponsa</td><td>Inotuzumab Ozogamicin</td><td>Pfizer, American pharmaceutical company</td><td>2017/06/28</td><td>CD22</td><td>B-cell acute lymphoblastic leukemia</td></tr><tr><td>Lumoxiti</td><td>Moxetumomab Pasudotox</td><td>AstraZeneca</td><td>2018/09/13</td><td>CD22</td><td>Capillary leukemia</td></tr><tr><td>Polivy</td><td>Polatuzumab Vedotin</td><td>F. Hoffmann-La Roche Ltd</td><td>2019/06/10</td><td>CD79b</td><td>Diffuse large B-cell lymphoma</td></tr><tr><td>Padcev</td><td>Enfortumab Vedotin</td><td>SEAGEN/Anstellar</td><td>2019/12/18</td><td>Nectin-4</td><td>Urothelial carcinoma</td></tr><tr><td>Enhertu</td><td>Trastuzumab Deruxtecan</td><td>Daiichi Sankyo/AstraZeneca</td><td>2019/12/20</td><td>HER2</td><td>HER2-positive breast cancer</td></tr><tr><td>Trodelvy</td><td>Sacituzumab Govitecan</td><td>Gilead, an American pharmaceutical company</td><td>2020/04/22</td><td>Trop-2</td><td>Triple-negative breast cancer</td></tr><tr><td>Blenrep</td><td>Belantamab Mafodotin</td><td>GSK</td><td><p>2020/08/05 (first approved)</p><p>2022/11/22 (withdrawn from the market)</p></td><td>BCMA</td><td>Multiple myeloma</td></tr><tr><td>Akalux</td><td>Cetuximab Saratolacan</td><td>Rakuten Medical</td><td>2020/09/25</td><td>EGFR</td><td>Head and neck cancer</td></tr><tr><td>Zynlonta</td><td>Loncastuximab Tesirine</td><td>ADC Therapeutics</td><td>2021/04/23</td><td>CD19</td><td>B-cell lymphoma</td></tr><tr><td>Disitamab Vedotin</td><td>Vidicilimumab</td><td>Rongchang Bio</td><td>2021/06/08</td><td>HER2</td><td>Gastric cancer</td></tr><tr><td>Tivdak</td><td>Tisotumab Vedotin</td><td>Genmab/Seagen</td><td>2021/09/20</td><td>TF</td><td>Cervix</td></tr><tr><td>Elahere</td><td>Mirvetuximab Soravtansine</td><td>ImmunoGen/Donghua Pharmaceuticals</td><td>2022/11/14</td><td>FR&#x003b1;</td><td>Epithelial ovarian, Fallopian tube, Primary peritoneal cancer</td></tr></tbody></table><table-wrap-foot><p><italic>HER2</italic> human epidermal growth factor receptor 2, <italic>TROP2</italic> trophoblast cell surface antigen 2, <italic>BCMA</italic> B cell maturation antigen, <italic>EGFR</italic> epidermal growth factor receptor, <italic>TF</italic> tissue factor, <italic>FR&#x003b1;</italic> folate receptor alpha.</p></table-wrap-foot></table-wrap></p><p id="Par15">Over the past decade, substantial progress has been made in the development of ADCs [<xref ref-type="bibr" rid="CR18">18</xref>], driven by the identification of more potent cytotoxic agents, the refinement of bio-conjugation techniques, improved antigen targeting, and advancements in antibody engineering. However, ADCs continue to encounter significant challenges, including limited tumor penetration, toxicity, and the emergence of drug resistance. To overcome these obstacles, research has concentrated on novel antibody formats, innovative delivery systems, non-internalizing targets, novel cytotoxic agents, and precise site-specific conjugation strategies. Currently, over 100 ADC candidates are undergoing clinical evaluation [<xref ref-type="bibr" rid="CR18">18</xref>]. Although many of these innovations remain unvalidated in clinical practice, preliminary research has produced promising results. This review aims to provide an overview of the latest developments in ADC technology, address current challenges and unresolved issues, and explore potential future directions in this rapidly advancing field.</p></sec><sec id="Sec4"><title>Antibody-drug conjugate</title><sec id="Sec5"><title>Components</title><p id="Par16">An ADC consists of three essential components: an antibody, a cytotoxic payload and a linker (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The antibody is engineered to specifically bind to target molecules expressed on tumor cells. Upon binding, the cytotoxic payload is delivered, resulting in the selective destruction of the tumor cells, thereby enabling targeted cancer therapy [<xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><title>Antibody-drug conjugate (ADC) structure and key properties.</title><p>ADC is a complex structure composed of three key components. These include the antibody, the cytotoxic payload, and the linker that connects them, with each part playing an essential role.</p></caption><graphic xlink:href="41420_2025_2429_Fig3_HTML" id="d33e643"/></fig></p><sec id="Sec6"><title>Recombinant mAbs</title><p id="Par17">The mAbs are immunoglobulins with high specificity (mono-specificity) for a particular antigen or epitope [<xref ref-type="bibr" rid="CR20">20</xref>]. Initially, antibodies used in ADC development were derived from mice. However, their high failure rates were attributed to severe side effects caused by immunogenicity, which refers to an antigen&#x02019;s ability to provoke an immune response. This response is triggered by the antigen, leading to the activation, proliferation, differentiation, and production of antibodies and sensitized lymphocytes by specific immune cells [<xref ref-type="bibr" rid="CR21">21</xref>]. With the introduction of recombinant technology, murine antibodies were gradually replaced by chimeric and humanized antibodies, resulting in reduced immunogenicity [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The majority of ADCs now employ fully humanized antibodies, further minimizing immunogenicity. Among the 15 approved ADCs (Table <xref rid="Tab1" ref-type="table">1</xref>), only Brentuximab vedotin utilizes chimeric antibodies [<xref ref-type="bibr" rid="CR24">24</xref>]. Most ADCs incorporate immunoglobulin G (IgG) as the antibody backbone, which consists of four subtypes: IgG1, IgG2, IgG3, and IgG4 [<xref ref-type="bibr" rid="CR18">18</xref>], all of which are key components of serum immunoglobulins. Humanized mAbs effectively reduce ADC immunogenicity and side effects. Subtle differences among these IgG subclasses can impact mAb solubility, half-life, and affinity for various Fc&#x003b3; receptors (Fc&#x003b3;R) expressed in immune effector cells [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. IgG1, which shares a long serum half-life with IgG2 and IgG4, is the most abundant IgG subtype in serum. However, compared to other IgG subclasses, IgG1 binds more efficiently to the Fc&#x003b3;R, making it the preferred subtype for ADCs [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par18">Recombinant mAbs play a vital role in mediating antitumor effects by specifically targeting antigens on tumor cells. This enables the precise delivery of cytotoxic drug payloads directly to the tumor site [<xref ref-type="bibr" rid="CR23">23</xref>]. However, antibody production, storage, and transportation may induce modifications that compromise their structural integrity and biological activity, thereby affecting the efficacy of ADCs [<xref ref-type="bibr" rid="CR18">18</xref>]. An ideal monoclonal antibody should exhibit a high binding affinity for the target antigen, promote efficient internalization, have low immunogenicity, and maintain a prolonged plasma half-life [<xref ref-type="bibr" rid="CR28">28</xref>]. The internalization efficiency of ADCs is largely influenced by the affinity between the antibody and the tumor cell surface antigen. While increased affinity typically accelerates internalization, excessively high-affinity antibodies may limit penetration into solid tumors [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Thus, optimizing the affinity between the antigen and antibody is critical during drug development to ensure effective cellular uptake and enhanced anticancer activity.</p></sec><sec id="Sec7"><title>Cytotoxic Payload</title><p id="Par19">Cytotoxic payloads, which are small-molecule drugs, are engineered to selectively eliminate tumor cells [<xref ref-type="bibr" rid="CR30">30</xref>]. Due to the limited bioavailability of ADCs&#x02014;only approximately 2% reach the target tumor site following intravesical administration&#x02014;the payload compounds must possess high toxicity, typically with IC50 values in the nM to pM range [<xref ref-type="bibr" rid="CR18">18</xref>]. The efficacy of an ADC in delivering cytotoxic agents depends on three primary factors: the number of target cell surface antigens available for antibody binding, the internalization efficiency of the antigen-antibody complex, and the release of active cytotoxic agents from the intracellular antigen-antibody complex. Currently, ADC payloads exert their therapeutic effects primarily by disrupting microtubule polymerization and inducing deoxyribonucleic acid (DNA) damage [<xref ref-type="bibr" rid="CR31">31</xref>]. This approach emphasizes the targeted and precise mechanism of ADCs in eliminating cancer cells.</p></sec><sec id="Sec8"><title>Linkers</title><p id="Par20">Cytotoxic payloads in ADCs are conjugated to the antibody via a linker, which must remain stable in vivo to ensure ADC integrity until it reaches the tumor cell. However, this linkage should be easily cleaved upon internalization. Maintaining ADC stability during circulation is essential to prevent premature payload release due to linker degradation, which could cause damage to healthy tissues. Simultaneously, ADCs must be capable of efficiently releasing their cytotoxic payloads once internalized by the target cells. Linkers are classified as cleavable or non-cleavable. Non-cleavable linkers include two main categories: thioether and maleimidocaproyl [<xref ref-type="bibr" rid="CR32">32</xref>]. Cleavable linkers are further divided into three types: acid-cleavable, reducible disulfides, and those cleaved by exogenous stimuli [<xref ref-type="bibr" rid="CR33">33</xref>]. Within the cleavable category, linkers can be potential of pH-sensitive, protease-sensitive, or glutathione-sensitive, based on their specific characteristics [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Cleavable linkers are designed to break down in response to the distinct conditions of the tumor microenvironment, promoting the release of small molecule payloads. In contrast, non-cleavable linkers remain stable in both the bloodstream and tumor cells. When the ADC antibody is degraded in the lysosome, the small cytotoxic molecules, still attached to the linker, are released, exerting their anti-tumor effects [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec></sec><sec id="Sec9"><title>Development of ADCs</title><p id="Par21">ADCs are sophisticated constructs consisting of recombinant mAbs, cytotoxic agents, and linkers. Their development reflects significant advances in monoclonal antibody, payload, and linker technologies. The concept of ADCs was introduced by Paul Ehrlich in 1913 with his &#x0201c;magic bullet&#x0201d; theory. However, due to the technological limitations of that era, ADCs were first tested in animals in 1972, followed by human trials in 1983. A major breakthrough occurred in 1988 with the advent of humanized antibody technology, which mitigated the immunogenicity issues associated with murine antibodies, marking a pivotal moment in ADC development. Since then, the field has experienced rapid growth, and ADCs remain a dynamic focus of cancer therapeutic research [<xref ref-type="bibr" rid="CR36">36</xref>]. Their application in oncology has garnered substantial interest and has led to widespread clinical utilization (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Term occurrence network visualization of ADCs.</title><p><bold>A</bold> The term clustering based on different field. <bold>B</bold> A chronological overview of terms based on 2016&#x02013;2024. Each node in the map represents a term that occurred at least 5 times and the size of the node of a term is proportional to the number of occurrences of that term. The Core Collection of Web of Science (WOSCC) was used to retrieve and obtain relevant literatures on application of ADCs in tumor therapy since 2010&#x02013;2024. All articles were retrieved on the same day to prevent partial results confusion due to rapid updates of subsequent publications.</p></caption><graphic xlink:href="41420_2025_2429_Fig4_HTML" id="d33e751"/></fig></p><p id="Par22">Keywords are a fundamental component of academic articles, effectively capturing the central themes of a paper. In this study, all keywords from the retrieved publications were extracted and analyzed using VOSviewer software. A total of 369 keywords, each occurring at least five times, were included in the visualization. The size of the nodes reflects the frequency of the corresponding keywords, with larger nodes indicating higher frequency. The proximity between nodes represents the strength of the correlation between the terms, while nodes of the same color denote related topics (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>). As expected, keywords associated with &#x0201c;antibody-drug conjugates&#x0201d; such as targeted therapy, immunotherapy, human epidermal growth factor receptor 2 (HER2), breast cancer (BC), and prognosis are prominently featured. Similar to the analysis of research themes, all keywords were categorized into 12 primary clusters.</p><p id="Par23">Figure <xref rid="Fig4" ref-type="fig">4B</xref> illustrates the chronological evolution of keyword usage over time, derived from the analysis in Fig. <xref rid="Fig4" ref-type="fig">4A</xref>. Purple-marked terms indicate their predominant usage in earlier years, while green denotes those that have remained consistently relevant. For instance, terms like brentuximab vedotin and adenocarcinoma were frequently used prior to 2016, whereas keywords such as trastuzumab deruxtecan, disitamab vedotin, gold nanoparticles, and tumor microenvironment have gained prominence in recent years.</p><p id="Par24">In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC, Mylotarg (gemtuzumab ozogamicin), for the treatment of adult acute myeloid leukemia, marking a significant milestone in the development of targeted ADC therapies for cancer [<xref ref-type="bibr" rid="CR18">18</xref>]. However, post-approval studies revealed that Mylotarg was linked to fatal liver toxicity and failed to demonstrate a statistically significant improvement in overall survival (OS). As a result, the drug was withdrawn from the market in 2010 [<xref ref-type="bibr" rid="CR37">37</xref>]. Despite this setback, Mylotarg remains a focus of ongoing scientific research. After further development, the FDA re-approved Mylotarg in 2017 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], reflecting the persistent efforts to refine and enhance ADC-based therapies for cancer treatment.</p><p id="Par25">Advancements in ADC technology primarily aim to optimize antibodies, payloads, and conjugation methods to ensure targeted drug release at the tumor site, maximizing efficacy while minimizing off-target effects [<xref ref-type="bibr" rid="CR39">39</xref>]. ADC efficacy is closely linked to the concentration of cytotoxic drugs within tumor cells [<xref ref-type="bibr" rid="CR40">40</xref>]. The drug-antibody ratio (DAR), which represents the average number of cytotoxic molecules attached to each antibody, is a critical determinant of efficacy. Numerous studies have sought to enhance the DAR of ADCs [<xref ref-type="bibr" rid="CR41">41</xref>]. However, while an increased DAR can improve efficacy, it may also exacerbate toxicity to normal tissues due to the polar nature of the cytotoxic agents [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. A DAR range of 3.5-4 is generally considered optimal, as values above 4 may result in suboptimal pharmacokinetic profiles and increased toxicity [<xref ref-type="bibr" rid="CR44">44</xref>]. An exception to this is the development of an innovative cell-selective nanotoxin, based on anti-CD44 antibody-polymersome-DM1 conjugates (aCD44-AP-DM1), which achieves a DAR of up to 275 and promotes rapid, reductive release of DM1, offering potent treatment potential for solid tumors [<xref ref-type="bibr" rid="CR45">45</xref>]. Consequently, precise determination and selection of the DAR are essential for optimizing ADC development, ensuring effective drug concentrations within tumor cells.</p><p id="Par26">The technological development of ADCs has progressed through three distinct phases [<xref ref-type="bibr" rid="CR18">18</xref>], reflecting their complex structure and function. The first generation primarily involved conventional chemotherapeutic agents linked to mouse-derived antibodies via non-cleavable linkers, unstable connectors, and random coupling methods. These early technologies resulted in ADCs with high immunogenicity, unstable DAR, increased risk of linker cleavage in the bloodstream, and premature release of cytotoxic drugs. Consequently, these ADCs exhibited high toxicity, severely limiting their therapeutic window. In the second generation, humanized antibodies were introduced, along with more stable linkers, although random coupling techniques were still employed. These improvements reduced the immunogenicity of the antibodies, lowering their clearance rate by the immune system and enhancing target binding. Furthermore, the stability of the linker in plasma was improved, leading to a notable increase in the therapeutic window. Despite these advances, issues such as off-target toxicity, a limited therapeutic window, and aggregation or rapid clearance of ADCs with high DAR persisted. The third generation introduced targeted coupling methods, resulting in greater molecular homogeneity and improved ADC stability. This technology also enhanced in vivo stability and adopted strategies focused on achieving high DAR with minimal toxicity. These innovations, characterized by reduced toxicity, enhanced anticancer activity, and improved stability, have significantly advanced the effectiveness of ADC-based therapies [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec10"><title>Mechanism of action</title><p id="Par27">An ADC molecule enters tumor tissue via the vasculature, where it binds to a specific target on the tumor cell surface. This binding triggers internalization through the endosomal-lysosomal pathway. Within this pathway, the linker is cleaved, or the antibody is degraded, resulting in the release of the cytotoxic payload. The payload then diffuses into the cytoplasm and targets microtubule proteins, disrupting microtubule dynamics and inhibiting tumor growth. Certain payloads, such as calicheamicin, which target DNA, must further diffuse from the cytoplasm into the nucleus to exert their effects. If the cytotoxic metabolite is capable of passing through the cell membrane, it can diffuse into neighboring cells, inducing &#x02018;bystander killing&#x02019;. This process enhances the overall efficacy of the ADC by impacting not only the targeted cells but also surrounding tumor cells (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>ADCs follow a defined mechanism of action: Initially, they circulate through the bloodstream to reach tumor tissues (&#x02460;), where they bind to cell surface antigens. This interaction induces internalization of the ADC-antigen complex via antigen-mediated endocytosis (&#x02461;), followed by processing within the endo-lysosomal pathway (&#x02462;), which involves linker cleavage and potential antibody degradation. Once inside the cell, the drug payload is released. Depending on its type (&#x02463;), such as microtubule-disrupting or DNA-targeting agents, it exerts its effects in distinct cellular compartments. Accumulation of the active drug ultimately triggers cancer cell death. Cytotoxic metabolites released during this process may diffuse to adjacent cells, contributing to bystander killing (&#x02464;). Moreover, the Fc region of the antibody can enhance immune cell activity (&#x02465;), promoting immune-mediated tumor cell destruction.</p></caption><graphic xlink:href="41420_2025_2429_Fig5_HTML" id="d33e827"/></fig></p></sec><sec id="Sec11"><title>Limitations of ADCs</title><sec id="Sec12"><title>Pharmacokinetics</title><p id="Par28">Pharmacokinetics examines the dynamic processes governing a drug&#x02019;s absorption, distribution, metabolism (biochemical conversion), and excretion, with a particular focus on blood concentration over time [<xref ref-type="bibr" rid="CR49">49</xref>]. Drug development must address both safety and efficacy considerations. ADCs, being complex pharmaceuticals composed of multiple components, pose significant challenges in research and development, particularly regarding their pharmacokinetic properties. Following administration, ADCs can exist in several forms within the body, including the intact ADC, naked antibodies resulting from linker degradation, and free payloads [<xref ref-type="bibr" rid="CR50">50</xref>]. These forms continuously change as ADCs bind to their target antigens, undergo internalization, and subsequently dissociate. The concentration of intact ADCs and naked antibodies decreases after administration due to internalization and subsequent antibody clearance. This process is influenced by the mononuclear phagocyte system and Fc receptor (FcRn)-mediated recycling, where the FcRn binds ADCs in endocytic vesicles and transports them to extracellular spaces for reuse. As a result, antibodies, including both intact ADCs and naked antibodies, typically exhibit longer half-lives compared to conventional small-molecule drugs.</p><p id="Par29">Free-carrier drugs are predominantly metabolized in the liver and eliminated through urine or feces. This metabolic process can be affected by drug-drug interactions, as well as conditions like hepatic or renal impairment [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec13"><title>Drug resistance</title><p id="Par30">Numerous studies [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref>] have highlighted the substantial benefits of ADCs in the treatment of various cancers. However, as research advances, drug resistance has become a significant obstacle that requires attention. Tumor cells can develop resistance mechanisms in response to any therapeutic intervention [<xref ref-type="bibr" rid="CR56">56</xref>]. Resistance may manifest either after drug administration (secondary or acquired resistance) or at the onset of treatment (primary or denovo resistance).</p><sec id="FPar1"><title>Mechanisms underlying resistance to ADC therapies</title><p id="Par31">Drug resistance during ADC therapy is influenced by multiple factors, such as downregulation of target antigen expression, modifications in ADC transport mechanisms, defects in internalization, overexpression of drug efflux transporters, and alterations in apoptotic signalling pathways [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par32">One major factor is the downregulation or loss of target antigens, which can reduce ADC effectiveness. Mutations in the antigen that mAbs recognize, coupled with increased drug exposure, can significantly lower the expression levels of the target antigen. However, reduced drug exposure may enhance the efficacy of ADCs by preventing excessive antigen expression. Studies have shown that caveolin-1-mediated endocytosis of trastuzumab in HER2<sup>+</sup> cell lines reduces drug sensitivity. This is because diminished antigen expression limits the efficient delivery of trastuzumab to the lysosome [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par33">Autophagy also plays a critical role in modulating drug resistance through multiple mechanisms. ADC drugs release their cytotoxic payload via chemical or enzymatic cleavage within the lysosome, making the lysosomal environment a key player in ADC resistance [<xref ref-type="bibr" rid="CR58">58</xref>]. The involvement of autophagy in cancer is complex. While autophagy functions as a tumour suppressor in early stages of cancer development, it also promotes tumour progression during carcinogenesis and in later stages of cancer [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>]. Autophagy has been shown to increase cellular tolerance to drugs by lowering the levels of pro-apoptotic proteins, such as B-cell lymphoma-2 (BCL-2), while elevating anti-apoptotic proteins like BCL-2-associated X protein (BAX) [<xref ref-type="bibr" rid="CR63">63</xref>]. Furthermore, prolonged exposure to trastuzumab leads to its accumulation in the lysosome, contributing to drug resistance. This resistance is associated with an elevated lysosomal pH, which inhibits the release of cytotoxins by lysosomal proteases [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par34">Another factor is the overexpression of drug efflux transporters, which plays a significant role in ADC resistance. For instance, in HER2<sup>+</sup> BC cells sensitive to trastuzumab, cyclin B levels, which are involved in the G2/M transition, are elevated compared to those in trastuzumab-resistant cells [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par35">Finally, the upregulation of multidrug resistance genes can alter microtubule composition, resulting in reduced antigen expression, impaired antigen internalization by ADCs, and decreased intracellular trafficking or drug release [<xref ref-type="bibr" rid="CR65">65</xref>].</p></sec><sec id="FPar2"><title>Strategies to overcome ADC drug resistance</title><p id="Par36">In response to the multifaceted causes of drug resistance outlined above, the scientific and medical communities must establish a collaborative intervention system encompassing drug development, clinical application, and public health management. To address these challenges, sciences propose the following multidimensional improvement strategies: optimizing antibodies targeting antigen mutations, optimizing linkers targeting lysosomal transport proteins, optimizing cytotoxins, optimizing multidrug resistance gene (MDR) pathways, and autophagy inhibitor co-administered with ADCs.</p><p id="Par37">One potential solution to overcoming ADC resistance is optimizing the antibodies used, particularly through targeting antigen mutations. The use of bispecific and dual-epitope antibodies can improve the cellular uptake of ADCs. Bispecific ADCs bind two distinct, non-overlapping epitopes on the same target antigen, leading to enhanced receptor clustering and increased endocytosis, lysosomal transport, and degradation [<xref ref-type="bibr" rid="CR66">66</xref>]. Compared to HER2-targeted ADCs, bispecific ADCs targeting both HER2 and prolactin receptors are more effective in killing cells co-expressing both receptors, suggesting that dual targeting promotes enhanced lysosomal endocytosis [<xref ref-type="bibr" rid="CR67">67</xref>]. This approach addresses antigenic escape mechanisms while leveraging cooperative receptor dynamics.</p><p id="Par38">Another key area of focus is improving the linkers that target lysosomal transport proteins. An increase in lysosomal pH causes trastuzumab to accumulate in the lysosome, disrupting its proteolytic activity. Many ADCs rely on the lysosomal internalization and degradation pathway to deliver their cytotoxic payloads. Thus, restoring lysosomal function could overcome ADC resistance and improve efficacy. Studies suggest that restoring the antitumour activity of trastuzumab and other ADCs can be achieved by modulating lysosomal pH, and some research proposes utilizing light-activated nanoparticles to manipulate lysosomal pH [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par39">Optimizing the cytotoxins is another approach. For example, novel payloads, such as pyrrolo[2,3-d] pyrimidine benzodiazepines [<xref ref-type="bibr" rid="CR69">69</xref>], which bind to and cross-link specific DNA targets in cancer cells, can inhibit tumour cell proliferation without distorting the DNA helix, potentially reducing the risk of resistance development.</p><p id="Par40">Addressing MDR gene pathways can also help overcome ADC resistance. Multidrug resistance genes exhibit a higher affinity for transporting hydrophobic compounds compared to hydrophilic ones. Developing hydrophilic or charged linkers may enhance the potency of ADCs against MDR<sup>+</sup> cells with high polarity or charged metabolites. Singh et al. [<xref ref-type="bibr" rid="CR70">70</xref>] designed ADCs using a novel trisaccharide peptide linker (CX), which cleaves a single peptide bond to release the cytotoxic payload within the lysosome. Compared to SMCC-linker ADCs, the CX-linker ADC demonstrated significantly higher cytotoxic activity, with an IC50 reduction of 5 to 100 times in multidrug-resistant cell lines. Tian et al. [<xref ref-type="bibr" rid="CR71">71</xref>] developed a stable oxime bond linker between anti-5T4 and HER2 antibodies using MMAD and pacetylphenylalanine (pAcF), which improved both the stability and efficacy of the drug compared to conventional cysteine conjugates.</p><p id="Par41">Autophagy inhibitors co-administered with ADC have also emerged as a promising strategy. For example, phosphoinositide 3-Kinase/Protein Kinase B (PI3K/AKT) inhibitors, such as Alpelisib, in combination with HER2-targeted therapies, can overcome drug resistance. Tian et al. [<xref ref-type="bibr" rid="CR72">72</xref>] developed a stable oxime bond linker between anti-5T4 and HER2 antibodies using MMAD and pAcF, which improved both the stability and efficacy of the drug compared to conventional cysteine conjugates. A novel PI3K-p110&#x003b1; Proteolysis Targeting Chimera (PROTAC) has been developed, which effectively inhibits breast cancer cell proliferation by degrading PI3K-p110&#x003b1; and restores sensitivity to lapatinib. Furthermore, the clinical efficacy of the PI3K PROTAC exceeds that of Alpelisib, a selective PI3K-p110&#x003b1; kinase inhibitor [<xref ref-type="bibr" rid="CR73">73</xref>]. The autophagy inhibitor LY294002 significantly enhanced the cytotoxicity of &#x003b1;CLDN18.2-MMAE and caspase-mediated apoptosis, highlighting the protective role of autophagy in CLDN18.2-targeted ADC-treated GC cells [<xref ref-type="bibr" rid="CR62">62</xref>]. Co-administration with autophagy inhibitors markedly improved the in vivo antitumour efficacy of &#x003b1;CLDN18.2-MMAE. Additionally, combining ADCs with immune checkpoint inhibitors has yielded promising therapeutic outcomes in several clinical trials. One study proposed a novel treatment strategy by combining nectin-4 MMAE with autophagy inhibitors for bladder cancer therapy [<xref ref-type="bibr" rid="CR74">74</xref>]. In contrast, autophagy inhibition by chloroquine suppressed Rituximab-MMAE-induced apoptosis, while autophagy activation by rapamycin significantly enhanced the therapeutic effect of Rituximab-MMAE in both in vitro and in vivo models [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par42">These approaches may offer a pathway to more effective cancer therapies.</p></sec></sec><sec id="Sec14"><title>Toxicity</title><p id="Par43">Several studies have identified key toxicities associated with ADCs in animal models, including hematopoietic stem cell depletion [<xref ref-type="bibr" rid="CR76">76</xref>], hepatotoxicity [<xref ref-type="bibr" rid="CR77">77</xref>], and reproductive toxicity [<xref ref-type="bibr" rid="CR78">78</xref>]. Other reports highlight dermatotoxicity and nephrotoxicity [<xref ref-type="bibr" rid="CR79">79</xref>]. Additionally, certain solid tumor cells may evade ADC targeting due to heterogeneous antigen expression, resulting in the &#x0201c;bystander effect&#x0201d; [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. In some cases, antibody-induced toxicity is observed, as seen in the dermal toxicity linked to Pfizer&#x02019;s trophoblast cell surface antigen 2 (Trop2) ADC, potentially caused by antigen expression in epithelial tissues [<xref ref-type="bibr" rid="CR82">82</xref>]. However, in most instances, toxicities are primarily attributed to the cytotoxic payloads [<xref ref-type="bibr" rid="CR83">83</xref>]. For example, microtubule inhibitors such as monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) can lead to neutropenia and thrombocytopenia, while kacinomycin is associated with liver injury. Due to their relatively large molecular size, ADCs tend to accumulate in tumor tissues [<xref ref-type="bibr" rid="CR84">84</xref>], limiting their penetration into tumor cells and reducing therapeutic efficacy [<xref ref-type="bibr" rid="CR85">85</xref>]. ADCs consist of an antibody conjugated to a payload via a linker [<xref ref-type="bibr" rid="CR86">86</xref>], which ensures stability in the body and promotes controlled payload release within the lysosome of target tumor cells. Achieving this balance requires optimizing both the linker&#x02019;s stability and the efficient cleavage of the payload from the ADC [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par44">The combination of these factors, along with patient variability, complicates the development of a model to characterize the clinical features of ADCs, further increasing the challenges in designing novel ADCs. Additionally, molecular aggregation of ADCs, influenced by antibody structure, hydrophilic-hydrophobic interactions, and external environmental factors, has been shown to diminish the therapeutic efficacy of the drug [<xref ref-type="bibr" rid="CR88">88</xref>]. Therefore, optimizing next-generation ADCs requires not only design improvements but also vigilant monitoring of adverse reactions during drug administration to mitigate potential risks.</p></sec></sec></sec><sec id="Sec15"><title>ADCs in GC treatment</title><sec id="Sec16"><title>Target: HER2</title><p id="Par45">HER2, also referred to as erythroblastic leukemia viral oncogene homolog 2 (ERBB2), is a distinct member of the ERBB family [<xref ref-type="bibr" rid="CR89">89</xref>]. Unlike other ERBB receptors, HER2 lacks ligand-binding capacity and instead forms heterodimers with other ERBB family members. This interaction triggers the phosphorylation of intracellular tyrosine kinases, activating downstream signaling pathways [<xref ref-type="bibr" rid="CR90">90</xref>].</p><p id="Par46">HER2 plays a key role in regulating specific signaling pathways within the tumor microenvironment, which are essential for various cellular processes, including proliferation, apoptosis, migration, and angiogenesis [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>].</p><p id="Par47">Through heterodimerization with HER3, HER2 activates the PI3K/AKT/mTOR pathway, promoting cell survival, metabolic reprogramming, and resistance to therapy [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Additionally, HER2 activates RAS via the Grb2/SOS complex, which further stimulates the mitogen-activated protein kinase/extracellular rignal-regulated kinase pathway (MAPK/ERK) cascade, enhancing proliferation and epithelial-mesenchymal transition (EMT), thereby promoting metastasis [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. HER2 also activates the JAK/STAT pathway by inducing cytokines like interleukin-6 (IL-6), which in turn upregulates programmed death-ligand 1 (PD-L1), suppressing T-cell function and promoting cancer stem cell (CSC) self-renewal [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Moreover, HER2 activates Src kinase, which drives cytoskeletal remodeling and extracellular matrix degradation, enabling cellular invasion [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Activation of the nuclear factor kappa-B (NF-&#x003ba;B) pathway through PI3K/AKT or Src contributes to a pro-inflammatory microenvironment and the upregulation of anti-apoptotic proteins [<xref ref-type="bibr" rid="CR101">101</xref>]. Additionally, HER2 stabilizes Wnt/&#x003b2;-catenin signaling by inhibiting GSK3&#x003b2;, reinforcing CSC maintenance and chemoresistance [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Lastly, HER2 remodels the immune microenvironment by recruiting immunosuppressive cells, such as Tregs and M2 macrophages, and increasing PD-L1 expression, collectively promoting immune evasion [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Therefore, targeting HER2 and its downstream signaling, in combination with immunomodulatory strategies, represents a promising therapeutic approach for HER2-positive GC.</p><p id="Par48">Trastuzumab, in combination with chemotherapy and PD-1 checkpoint blockade, is emerging as the new first-line standard of care for HER2-positive advanced GC. Results from phase 3 clinical trials are eagerly awaited [<xref ref-type="bibr" rid="CR106">106</xref>]. Recent years have seen substantial progress in the development of HER2-targeted therapies for GC.</p><sec id="Sec17"><title>RC48</title><p id="Par49">RC48 is a novel third-generation anti-HER2 ADC composed of Hertuzumab, a high-affinity anti-HER2 monoclonal antibody with enhanced antibody-dependent cytotoxic activity compared to trastuzumab, conjugated to MMAE through a cleavable linker [<xref ref-type="bibr" rid="CR107">107</xref>]. Upon internalization, RC48 selectively delivers MMAE to target cells [<xref ref-type="bibr" rid="CR108">108</xref>], leading to antiproliferative effects by disrupting the HER2 signaling pathway and associated bypass pathways, including PI3K/AKT/mTOR and MAPK signaling [<xref ref-type="bibr" rid="CR109">109</xref>]. This disruption results in G2/M phase cell cycle arrest via microtubule depolymerization and promotes apoptosis, thereby exerting antitumor effects [<xref ref-type="bibr" rid="CR110">110</xref>]. RC48 has shown significant antiproliferative activity in HER2-positive cells. Given its robust clinical efficacy in HER2-positive GC, it was granted approval by the National Medical Products Administration (NMPA) in 2021 for the treatment of patients with locally advanced or metastatic gastric and gastroesophageal junction cancer (GC/GEJC) with HER2 overexpression, who have undergone at least two prior systemic chemotherapy regimens [<xref ref-type="bibr" rid="CR111">111</xref>]. This approval was based on a single-arm, open-label, multicenter clinical trial enrolling 127 patients with HER2-overexpressing advanced GC and GEJC, who had previously received second-line or more chemotherapy regimens, such as vedolizumab. The trial reported an objective response rate (ORR) of 23.6%, a median progression-free survival (mPFS) of 4.1 months, and a median OS of 7.6 months (NCT02881190) [<xref ref-type="bibr" rid="CR112">112</xref>].</p></sec><sec id="Sec18"><title>T-DM1</title><p id="Par50">Trastuzumab emtansine (T-DM1) is an ADC composed of trastuzumab, the anti-mitotic microtubule inhibitor DM1, and a thioether-based linker, maleimide methyl cyclohexanecarboxylate [<xref ref-type="bibr" rid="CR113">113</xref>]. It is FDA-approved for the treatment of HER2-positive advanced BC [<xref ref-type="bibr" rid="CR114">114</xref>]. This approval opens the possibility for further exploration of T-DM1 as a targeted delivery system in GC. T-DM1 specifically delivers the apoptosis-inducing agent DM1 to HER2-positive tumor cells, functioning as a &#x0201c;precision missile.&#x0201d; Studies [<xref ref-type="bibr" rid="CR115">115</xref>] have demonstrated that T-DM1 exhibits robust antitumor activity against HER2-positive GC cells both in vitro and in vivo, including efficacy against trastuzumab-resistant tumors. However, a randomized, open-label, multicenter phase II/III trial [<xref ref-type="bibr" rid="CR116">116</xref>] found that T-DM1 did not show superiority over paclitaxel in previously treated HER2-positive advanced GC patients. In response, Seo et al. [<xref ref-type="bibr" rid="CR117">117</xref>] experimentally revealed that a substantial proportion of HER2-positive patients underwent HER2-negative transformation and increased genetic heterogeneity following chemotherapy with trastuzumab-based regimens. This downregulation of HER2 expression highlights the importance of reassessing HER2 status prior to initiating second-line anti-HER2 therapy.</p></sec><sec id="Sec19"><title>DS-8201a</title><p id="Par51">Trastuzumab Deruxtecan (DS-8201a) [<xref ref-type="bibr" rid="CR118">118</xref>], also known as T-DXd, is a second-generation ADC consisting of trastuzumab, a cleavable tetrapeptide linker, and the topoisomerase I inhibitor, DXd. Unlike T-DM1, which has a DAR of 3.5, T-DXd features a distinct DAR of 8, owing to its unique tetrapeptide linker (GGFG) [<xref ref-type="bibr" rid="CR119">119</xref>]. This linker is selectively cleaved by lysosomal enzymes within tumor cells, ensuring the targeted release of the drug while minimizing impact on the surrounding circulation [<xref ref-type="bibr" rid="CR120">120</xref>]. Upon binding to the HER2 receptor, T-DXd disrupts HER2 signaling and induces an antibody-dependent cellular cytotoxicity (ADCC) response [<xref ref-type="bibr" rid="CR121">121</xref>]. Additionally, T-DXd is internalized via endocytosis, undergoes cleavage within the lysosome, and releases the free DXd payload, resulting in DNA damage and subsequent apoptosis [<xref ref-type="bibr" rid="CR122">122</xref>]. In experiments using the HER2-positive GC cell line (NCI-N87) and a T-DM1-resistant variant (N87-TDMR) developed through continuous exposure to T-DM1, the efficacy of DS-8201a was assessed, suggesting its potential for treating T-DM1-resistant patients with BC or GC. Phase I clinical trials evaluating DS-8201a&#x02019;s therapeutic efficacy and safety have demonstrated its promising anti-tumor activity and manageable safety profile. As a result, the FDA approved DS-8201a in 2021 for use in patients with locally advanced or metastatic HER2-positive GC/GEJC who have previously undergone trastuzumab-based treatments.</p><p id="Par52">The ongoing DESTINY-Gastric 06 trial seeks to validate the survival benefits of DS-8201a in Chinese patients [<xref ref-type="bibr" rid="CR123">123</xref>]. Currently, the standard second-line treatment for advanced GC consists of a combination of ramucirumab and paclitaxel. To explore more effective alternatives, the DESTINY-Gastric 04 trial is also underway. Ogitani et al. [<xref ref-type="bibr" rid="CR124">124</xref>] reported anti-tumor activity in a patient-derived xenograft (PDX) model of BC with low HER2 expression. Additionally, a phase I pilot study assessing dosage toxicity in GC patients with low HER2 expression demonstrated significant antitumor effects. These results highlight the potential of this therapy for GC patients with low HER2 expression [<xref ref-type="bibr" rid="CR125">125</xref>]. T-DXd showed remarkable efficacy and an acceptable safety profile, owing to its unique DXd payload and stable linker.</p></sec><sec id="Sec20"><title>ARX788</title><p id="Par53">ARX788 [<xref ref-type="bibr" rid="CR126">126</xref>] is a novel ADC comprising an anti-HER2 mAb conjugated to the microtubule inhibitor AS269. This ADC is site-specifically coupled to the antibody using unnatural amino acids, resulting in high drug homogeneity and a relatively low DAR of approximately 2 [<xref ref-type="bibr" rid="CR127">127</xref>]. Once internalized by tumor cells, ARX788 releases amberstatin, which induces cell cycle arrest and apoptosis, thereby exerting anticancer effects. The non-cleavable linker, coupled with pAcF, allows ARX788 to mitigate the non-targeted toxicity observed in previous generations of ADCs. ARX788 has demonstrated efficacy against trastuzumab-resistant GC cells [<xref ref-type="bibr" rid="CR128">128</xref>]. In PDX models with high and low HER2 expression, treatment with ARX788 and T-DM1 showed that ARX788 exhibited stronger anticancer activity compared to T-DM1 [<xref ref-type="bibr" rid="CR129">129</xref>]. Furthermore, ARX788 displayed high serum stability and a relatively long half-life (~12.5 days) in mice. Skidmore et al. [<xref ref-type="bibr" rid="CR127">127</xref>] demonstrated in vitro that ARX788 was more effective in cell lines with low HER2 expression than T-DM1, while showing no activity in normal cardiomyocytes. Additionally, ARX788 significantly inhibited tumor growth, outperforming T-DM1 in BC with high HER1 and low HER2 expression, as well as in GC-derived xenografts.</p><p id="Par54">A recent phase I randomized, open-label, international multicenter trial [<xref ref-type="bibr" rid="CR128">128</xref>] assessed the efficacy of ARX788 in 30 patients with advanced GC. Compared to trastuzumab monotherapy, the combination of ARX788 and trastuzumab significantly improved OS, with an ORR of 37.9% [95% CI (20.7%, 57.7%)] and a disease control rate (DCR) of 55.2% [95% CI (35.7%, 73.6%)]. At a median follow-up of 10 months, the mPFS and OS were 4.1 months [95% CI (1.4, 6.4)] and 10.7 months [95% CI (4.8, not reached)], respectively, while the median duration of remission was 8.4 months [95% CI (2.1, 18.9)]. These results suggest that ARX788 demonstrates promising antitumor activity in patients with HER2-positive advanced gastric adenocarcinoma. Currently, a phase II/III international, multicenter, randomized controlled study is underway to further evaluate the efficacy and safety of ARX788 in second-line treatment for HER2-positive advanced GC/GEJC adenocarcinoma. This study provides valuable data and a theoretical foundation for subsequent clinical trials of this novel HER2-targeted ADC.</p></sec><sec id="Sec21"><title>MRG002</title><p id="Par55">MRG002 is an ADC consisting of sugar-modified trastuzumab conjugated to MMAE via a valine-citrulline linker, with a DAR of 3.8 [<xref ref-type="bibr" rid="CR130">130</xref>]. It exhibits a similar affinity for HER2 as trastuzumab but has reduced ADCC activity and minimal effects on immune cells due to the high fucosylation of its mAb component. In animal studies, MRG002 has been shown to induce tumor regression in a CDX model with low HER2 expression [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Preclinical data further demonstrate solid anti-tumor activity in mammary and gastric xenograft models with varying HER2 expression levels. MRG002 also outperformed both trastuzumab and T-DM1 monotherapy in mouse xenograft models. Additionally, MRG002 significantly enhanced the anti-tumor effects of anti-PD-1 mAb, suggesting a potential combination therapy for GC patients [<xref ref-type="bibr" rid="CR131">131</xref>]. A phase I trial of MRG002 as a monotherapy (NCT04941339) is currently underway in patients with HER2-positive relapsed or refractory GC. Meanwhile, several phase II trials are evaluating MRG002&#x02019;s efficacy in treating various malignancies with HER2-positive or low-HER2 expression, including an ongoing study in locally advanced or metastatic GC/GEJC with low HER2 expression [<xref ref-type="bibr" rid="CR132">132</xref>].</p></sec><sec id="Sec22"><title>Others</title><p id="Par56">Legochem Biosciences&#x02019; ADC (LCB-ADC) represents a novel class of HER2-targeted ADCs, composed of trastuzumab conjugated to MMAF via a sophisticated cleavable linker [<xref ref-type="bibr" rid="CR133">133</xref>]. n contrast to T-DM1, all LCB-ADCs incorporate cleavable linkers engineered to enhance anticancer activity through multiple mechanisms. Additionally, LCB-ADC demonstrates a more potent ADCC effect and a higher G2/M phase arrest rate compared to T-DM1 [<xref ref-type="bibr" rid="CR133">133</xref>]. It also exhibits significant anti-tumor efficacy. PF-06804103, another HER2-targeted ADC, offers a broader therapeutic window and extended indications relative to T-DM1. Moreover, it presents favorable pharmacokinetic properties, enhanced stability, and reduced off-target toxicity [<xref ref-type="bibr" rid="CR134">134</xref>]. A comprehensive clinical evaluation of LCB-ADCs in patients with GC is warranted.</p><p id="Par57">Alongside these agents, several other novel HER2-targeted ADCs, including XMT-1522 [<xref ref-type="bibr" rid="CR55">55</xref>], SYD985 [<xref ref-type="bibr" rid="CR135">135</xref>], BAT8001 [<xref ref-type="bibr" rid="CR136">136</xref>], ZW49 [<xref ref-type="bibr" rid="CR137">137</xref>], are undergoing clinical trials. The efficacy and safety of these therapies for patients with low HER2-expressing GC have attracted considerable interest (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Key clinical trials of HER2-targeted ADCs in gastric cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trial number</th><th>ADC</th><th>Stage</th><th>Patients</th><th>mOS</th><th>ORR</th><th>mPFS</th><th>Adverse</th><th>Refs</th></tr></thead><tbody><tr><td>NCT03556345</td><td>RC48</td><td>II</td><td>127</td><td>7.9 months</td><td>24.80%</td><td>5.5 months</td><td>Decreased WBC count: 53.6%; asthenia: 53.6%; hair loss: 53.6%; decreased neutrophil count: 52.0%; anemia: 49.6%; increased ASP SAEs: 36.0%; aminotransferase level: 43.2%.</td><td>[<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td>NCT02881190</td><td>RC48</td><td>I</td><td>57</td><td>7.6 months</td><td>23.60%</td><td>4.1 months</td><td>Neutropenia: 19.3%; leukopenia: 17.5%; hypoesthesia: 14.0%; conjugated blood bilirubin increased: 8.8%.</td><td>[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td>NCT01641939</td><td>T-DM1</td><td>II/III</td><td>204</td><td>7.9 months</td><td>20.60%</td><td>2.66 months</td><td>Alopecia: 51.35%; peripheral neuropathy: 19.82%; thrombocytopenia: 14.41%.</td><td>/</td></tr><tr><td>NCT02318901</td><td>T-DM1</td><td>I/II</td><td>16</td><td>/</td><td>/</td><td>/</td><td>Thrombocytopenia: 7.25%; fatigue: 19.64%; peripheral neuropathy: 9.38%.</td><td>/</td></tr><tr><td>NCT03329690</td><td>DS-8201a</td><td>II</td><td>233</td><td>8.4 months</td><td>/</td><td>3.5 months</td><td>Decreased neutrophil count:51% vs. 24%; anemia: 38% vs. 23%; decreased white cell count: 21% vs. 11% (DS-8201a vs. chemotherapy)</td><td>[<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td>NCT03329690</td><td>DS-8201a</td><td>II</td><td>233</td><td>7.8 months</td><td>26.30%</td><td>7.8 months</td><td>Anemia: 30.0% and 29.2%; decreased neutrophil count:25.0% and 29.2%; decreased appetite: 20.0% and 20.8% in cohort 1 and 2.</td><td>[<xref ref-type="bibr" rid="CR174">174</xref>]</td></tr><tr><td>NCT04014075</td><td>DS-8201a</td><td>II</td><td>79</td><td>/</td><td>42%</td><td>5.5 months</td><td>SAEs: 41.77%.</td><td>[<xref ref-type="bibr" rid="CR175">175</xref>]</td></tr><tr><td>NCT03255070</td><td>ARX788</td><td>I</td><td>106</td><td>10.7 months</td><td>37.90%</td><td>4.1 months</td><td>AEs: 93.3%.</td><td>[<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td>NCT02277717</td><td>SYD985</td><td>I</td><td>185</td><td>/</td><td>/</td><td>/</td><td>/</td><td>[<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>ADCs</italic> antibody-drug conjugates, <italic>mOS</italic> median overall survival, <italic>mPFS</italic> median progression-free survival, <italic>ORR</italic> objective response rate, <italic>Refs</italic> references, <italic>WBC</italic> white blood cell, <italic>SAEs</italic> serious adverse events, <italic>AEs</italic> adverse events, <italic>I/II/III</italic> cancer stage I/II/III.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec23"><title>Target: GCC</title><p id="Par58">Guanylate cyclase C (GCC) is a receptor for heat-resistant enterotoxins that induce diarrhea, as well as for the endogenous ligands guanosine and uroguanosine [<xref ref-type="bibr" rid="CR138">138</xref>]. It is primarily expressed in the intestinal epithelium [<xref ref-type="bibr" rid="CR139">139</xref>]. GCC plays a key role in regulating intestinal fluid and ion secretion, as well as inhibiting cell proliferation. Research has shown that, compared to normal tissues, GCC is overexpressed on the surface of malignant tumors, including those in peripheral blood and the intestine. Consequently, GCC is gaining attention as a potential target for ADCs [<xref ref-type="bibr" rid="CR140">140</xref>].</p><sec id="Sec24"><title>TAK-164</title><p id="Par59">TAK-164 is an ADC targeting glycoprotein-coupled receptors (GCC receptors) in colorectal cancer (CRC) and GC [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]. The construct consists of a 5F9 antibody backbone conjugated to a DNA-alkylating DGN-549 payload. Bruna examined the impact of coadministration of 5F9 on the distribution and efficacy of TAK-164 in a human tumor xenograft mouse model. Both experimental and computational data indicate that the observed effects were not attributable to tumor saturation, increased binding to perivascular cells, or compensatory bystander effects. Instead, the cellular potency of DGN-549 was aligned with the single-cell uptake of TAK-164, resulting in an IC50 close to its equilibrium binding affinity [<xref ref-type="bibr" rid="CR143">143</xref>]. In a separate clinical trial [<xref ref-type="bibr" rid="CR144">144</xref>], 31 patients with GCC-positive, advanced gastrointestinal cancers received intravenous TAK-164 on day 1 of 21-day cycles. No dose-limiting toxicities (DLTs) were observed during the evaluation period for cycle 1. However, following the second cycle, three patients experienced dose-limiting treatment-emergent adverse events, including grade 3 pyrexia and grade 5 hepatic failure (0.19&#x02009;mg/kg), grade 4 hepatic failure with a reduction in platelet count (0.25&#x02009;mg/kg), and grade 3 nausea along with grade 4 reductions in platelet and neutrophil counts (0.25&#x02009;mg/kg).</p><p id="Par60">TAK-164 demonstrated a manageable safety profile at 0.064&#x02009;mg/kg, although hepatic toxicity was identified as a potential risk. The recommended phase 2 dose (RP2D) of 0.064&#x02009;mg/kg was deemed insufficient to achieve clinical benefit, and no further clinical development was planned (NCT03449030).</p></sec><sec id="Sec25"><title>TAK-264</title><p id="Par61">TAK-264 is a novel ADC targeting GCC, comprising an IgG1 monoclonal antibody, the cytotoxic payload MMAE, and a protease-cleavable linker (peptide maleimide-hexanoyl-valine-citrulline). Preliminary animal studies have shown promising results in a high-expression GCC model, where TAK-264, via its protease-cleavable linker, delivers the potent anti-microtubule agent MMAE (linker and toxin licensed from Seattle Genetics) [<xref ref-type="bibr" rid="CR145">145</xref>]. Clinical trial data [<xref ref-type="bibr" rid="CR146">146</xref>] revealed that the most common side effects of TAK-264 were malignancy (41% of cases), loss of appetite (41%), fatigue (32%), and diarrhea (27%). The incidence of secondary adverse effects, including neutropenia and hypokalemia, was 22% and 7%, respectively, suggesting that TAK-264 is generally well tolerated. Among the 41 patients enrolled in the trial, one achieved partial remission, three had stable disease, and the mPFS was 44 days. These findings indicate that TAK-264 has limited efficacy in advanced GC patients but demonstrates a manageable safety profile. Preliminary evidence also suggests potential antitumor activity in specific gastrointestinal malignancies. Given the high expression of GCC in GC, this target remains a promising approach for the treatment of advanced GC. A further study [<xref ref-type="bibr" rid="CR147">147</xref>] supports these results, indicating a similar outcome.</p></sec></sec><sec id="Sec26"><title>Target: HER3</title><p id="Par62">The HER3 protein, a member of the HER receptor tyrosine kinase (RPTK) family, is expressed in various solid tumors. Due to its role in promoting cell proliferation, targeting HER3 could have clinical significance. It is now recognized that the activation of HER3&#x02019;s downstream signaling pathway plays a key role in modulating the therapeutic sensitivity of different tumor types. Overexpression of HER3 in GC patients is associated with poor prognosis.</p><sec id="Sec27"><title>EV20/NMS-P945</title><p id="Par63">EV20/NMS-P945 is an ADC composed of EV20, the thienylindole derivative NMS-P528, and a cleavable linker, with an average DAR of 3.6. This ADC demonstrates favorable stability and a prolonged terminal half-life [<xref ref-type="bibr" rid="CR148">148</xref>]. EV20/NMS-P945 exhibits target-dependent cytotoxicity in vitro against a range of cancers, including pancreatic, prostate, gastric, ovarian, and melanoma cell lines. Additionally, it shows promising anticancer activity in a mouse xenograft tumor model [<xref ref-type="bibr" rid="CR148">148</xref>]. The observed effectiveness may be attributed to the thienoindole derivative NMS-P528, which is highly active in heterogeneous tumors. This activity is enhanced by the bystander effect of the toxin in cancer cells with low cell doubling times, making it a promising therapeutic option for solid tumors. These results suggest that EV20/NMS-P945 may serve as an effective therapeutic strategy for targeting HER3.</p></sec><sec id="Sec28"><title>U3-1402</title><p id="Par64">U3-1402 consists of a humanized anti-HER3 IgG1 mAb conjugated to a large topoisomerase I inhibitor payload, an Ezetimibe derivative of DXd, through a cleavable tetrapeptide linker [<xref ref-type="bibr" rid="CR149">149</xref>]. This ADC offers several advantages, including high specificity, low toxicity, extended duration of action, and potent activity. It binds to HER3, which is overexpressed on the surface of tumor cells, forming the HER3-U3-1402 complex. This complex is then internalized into the endosome and subsequently processed by lysosomes. Inside the lysosome, a histone protease cleaves the linker, releasing the topoisomerase I inhibitor DXd, which induces DNA damage and impairs repair mechanisms [<xref ref-type="bibr" rid="CR150">150</xref>].</p><p id="Par65">In preclinical studies, U3-1402 demonstrated superior activity compared to the pattumab monoclonal antibody, showing therapeutic efficacy in cell lines resistant to first-generation tyrosine kinase inhibitors and in mouse models. Treatment was initiated when tumor volumes ranged from 80 to 250&#x02009;mm&#x000b3;, and as expected, U3-1402 significantly inhibited tumor growth compared to vehicle treatment [<xref ref-type="bibr" rid="CR151">151</xref>]. Data from a phase I clinical trial (NCT03260491) in patients with advanced non-small cell lung cancer reported a 100% disease control rate [<xref ref-type="bibr" rid="CR152">152</xref>]. Two ongoing clinical studies investigating HER3-positive BC have shown promising survival benefits, with ORR of 33% and 42.9%, respectively [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. .</p><p id="Par66">In addition to U3-1402, several other HER3-targeted ADCs, including MCLA-128 [<xref ref-type="bibr" rid="CR155">155</xref>], MM-121 [<xref ref-type="bibr" rid="CR156">156</xref>], and CDX/KTN3379 [<xref ref-type="bibr" rid="CR157">157</xref>], are currently under investigation in clinical trials. The results of these studies may offer hope for GC patients in the near future.</p></sec></sec><sec id="Sec29"><title>Target: CLDN18.2</title><p id="Par67">Claudin 18.2 (CLDN18.2) is a key structural protein involved in tight junctions between cells [<xref ref-type="bibr" rid="CR158">158</xref>]. While it is minimally expressed in normal tissues, it is highly upregulated in malignant tumors such as GC, pancreatic cancer, and esophageal cancer, positioning it as a promising target for tumor therapy. Recent advancements in CLDN18.2-targeted therapies have shown significant progress [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. Furthermore, emerging research suggests that CLDN18.2-positive GC may exhibit a distinct immune microenvironment [<xref ref-type="bibr" rid="CR161">161</xref>]. Combining CLDN18.2 targeting with immune activation may offer a synergistic therapeutic effect, potentially enhancing treatment outcomes in patients with advanced GC.</p><sec id="Sec30"><title>CMG901</title><p id="Par68">CMG901 is an ADC consisting of a humanized monoclonal antibody, CM311, targeting CLDN18.2, and the microtubule polymerization inhibitor MMAE, which is linked via a cleavable linker arm. The monoclonal antibody component of CMG901 selectively binds to CLDN18.2-positive cells, and upon binding, the ADC is internalized by tumor cells through endocytosis. Once inside the cell, the cleavable linker releases the cytotoxic MMAE payload within lysosomes, resulting in tumor cell apoptosis [<xref ref-type="bibr" rid="CR162">162</xref>]. CMG901 (AZD0901) has been approved by the FDA for a phase I clinical trial (NCT04805307) targeting advanced solid tumors, including gastric and pancreatic cancers, where it demonstrated an ORR of 33% and a DCR of 70% in 89 patients [<xref ref-type="bibr" rid="CR163">163</xref>].</p></sec><sec id="Sec31"><title>Others</title><p id="Par69">EO-3021 (SYSA1801) demonstrated efficacy in 17 GC patients (NCT05009966), with an ORR of 47.1% and a DCR of 64.7%. Preliminary evidence has emerged from the ongoing clinical trial of SOT102 (NCT05525286) that suggests the drugs may be effective in treating patients with GC/GEJC. However, it should be noted that the associated trial have been paused for the time being.</p><p id="Par70">In summary, CLDN18.2 is characterized by high expression specificity in tumor tissues, making it a promising target for drug development and potentially transforming the treatment landscape for GC [<xref ref-type="bibr" rid="CR161">161</xref>]. The molecular profiling of GC patients using multi-omics data can further explore the therapeutic potential of targeting CLDN18.2 in this context. Additionally, further clinical studies are required to determine the optimal dosing and effective combination strategies for targeted CLDN18.2 therapy.</p></sec></sec><sec id="Sec32"><title>Target: TROP2</title><p id="Par71">TROP2, a cell surface glycoprotein encoded by the TACSTD2 gene, is integral to regulating tumor growth by modulating various signaling pathways involved in tumor invasion, proliferation, and progression [<xref ref-type="bibr" rid="CR164">164</xref>]. As a result, TROP2 has gained significant attention as a therapeutic target, with ADCs targeting TROP2 currently under investigation. However, no TROP2-targeted ADCs have been approved for clinical use to date.</p><sec id="Sec33"><title>SKB264</title><p id="Par72">SKB264 is a novel ADC composed of a humanized monoclonal anti-TROP2 antibody linked to a topoisomerase I inhibitor via a cleavable linker [<xref ref-type="bibr" rid="CR165">165</xref>]. This design provides several advantages, including the specificity of the monoclonal antibody for tumor cell antigens and the high efficacy of the cytotoxic agent. Preliminary results from the international multicenter Phase I-II first-in-human trial of SKB264 (NCT04152499) indicated that 17 patients were assessed for efficacy, with an overall ORR of 35.3%, a DCR of 70.6%, and a partial response observed in one patient with GC. These initial findings suggest that SKB264 is effective in treating solid tumors, and the ongoing Phase II expansion study aims to explore additional indications. The potential benefits of this treatment include providing relief for patients with locally advanced, unresectable, or metastatic solid tumors resistant to standard therapies.</p></sec><sec id="Sec34"><title>IMMU-132</title><p id="Par73">IMMU-132 is a novel ADC developed by coupling a humanized anti-TROP2 monoclonal antibody (hRS7) with the active irinotecan metabolite SN-38 [<xref ref-type="bibr" rid="CR164">164</xref>]. A Phase I/II clinical trial (NCT01631552) demonstrated its antitumor efficacy in patients with TROP2-overexpressing gastric and pancreatic cancers. Additionally, IMMU-132 was shown to be more selective and safer than irinotecan, with a reduced incidence of diarrhea [<xref ref-type="bibr" rid="CR166">166</xref>]. However, further investigation is required to fully assess the efficacy of IMMU-132 in TROP2-positive advanced solid tumors.</p></sec></sec><sec id="Sec35"><title>Target: Nectin-4</title><p id="Par74">Nectin-4 (gene name PVRL4) is a member of the Nectin family within the immunoglobulin superfamily of proteins, with high expression in breast, ovarian, and gastric cancers. It is closely associated with tumorigenesis and metastasis [<xref ref-type="bibr" rid="CR167">167</xref>]. Nectin-4 promotes cancer cell proliferation and metastasis by activating the PI3K/AKT pathway and EMT-related signaling [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>]. Studies have shown that messenger ribonucleic acid (mRNA) and protein expression of Nectin-4 is elevated in GC tumor tissues compared to adjacent normal tissues, and its positive expression correlates with the OS of GC patients [<xref ref-type="bibr" rid="CR170">170</xref>]. These results suggest that Nectin-4 plays a significant role in GC development and may serve as a potential clinicopathological biomarker and therapeutic target in GC [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>].</p><sec id="Sec36"><title>Nectin-4 NDC</title><p id="Par75">Trivalent Nanobody (Nb), with a molecular weight of 42&#x02009;kDa, consists of two homologous Nectin-4 Nbs and a high-affinity Nb (15&#x02009;kDa) targeting human serum albumin [<xref ref-type="bibr" rid="CR173">173</xref>]. This Nb is conjugated to a microtubule inhibitor, MMAE, via maleimide linkers containing valine-citrulline cleavage sites, resulting in a DAR of 1. Trivalent Nb overcomes the limitations of traditional IgG-based ADCs by leveraging the unique advantages of nanoantibodies, including enhanced tumor tissue penetration and more uniform targeted binding. Significant tumor suppression was demonstrated in an in vivo model. Cytotoxicity assays using the cell counting kit-8 method showed that Nectin-4 nanobody-drug conjugates (NDC) inhibited growth by approximately 60% in the NCI-N87 cell line, and by 70% at nanomolar concentrations in the 293T-human-Nectin-4 cell line. Histological and immunohistochemical analyses revealed that tumor tissues treated with Nectin-4 NDC exhibited pronounced morphological alterations, including vacuolization, nucleolysis, reduced cell density, and disrupted cellular structure, suggesting that Nectin-4 NDC effectively induces apoptosis in gastric adenocarcinoma cells [<xref ref-type="bibr" rid="CR173">173</xref>].</p><p id="Par76">In summary, the advancement of ADC therapeutics heralds a transformative era in GC management. ADCs exhibit a fundamental distinction from conventional chemotherapy, undergoing continuous evolution and refinement. The paradigm of targeted delivery, potent therapeutic efficacy, and favorable safety profiles inherent to ADC therapeutics will persist and be further optimized (Table <xref rid="Tab3" ref-type="table">3</xref>). With ongoing technological innovations, ADC platforms are anticipated to deliver substantial clinical benefits to an expanding patient population.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Composition of ADCs targeting gastric cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>NCI thesaurus code</th><th>ADC</th><th>Therapeutic target</th><th>Antibody</th><th>Payload</th><th>Linker</th><th>DAR</th></tr></thead><tbody><tr><td>C169918</td><td>RC48</td><td>HER2</td><td>Hertuzumab</td><td>MMAE</td><td>VC</td><td>4</td></tr><tr><td>C82429</td><td>T-DM1</td><td>HER2</td><td>Trastuzumab</td><td>DM1</td><td>SMCC</td><td>3.5</td></tr><tr><td>C128799</td><td>DS-8201a</td><td>HER2</td><td>Trastuzumab</td><td>DXd</td><td>Tetrapeptide</td><td>8</td></tr><tr><td>C123917</td><td>ARX788</td><td>HER2</td><td>Anvatabart</td><td>Amberstatin269</td><td>pAcF</td><td>1.9</td></tr><tr><td>C174205</td><td>MRG002</td><td>HER2</td><td>Trastuzumab</td><td>MMAE</td><td>VC</td><td>3.8</td></tr><tr><td>C172821</td><td>LCB-ADC</td><td>HER2</td><td>Trastuzumab</td><td>MMAF</td><td>Undisclosed</td><td>2</td></tr><tr><td>C132112</td><td>XMT-1522</td><td>HER2</td><td>HT-19</td><td>AF-HPA</td><td>Fleximer polymer</td><td>12</td></tr><tr><td>C118674</td><td>SYD985</td><td>HER2</td><td>Trastuzumab</td><td>Duocarmycin</td><td>VC</td><td>2.8</td></tr><tr><td>C173966</td><td>BAT8001</td><td>HER2</td><td>Trastuzumab</td><td>Maytansine</td><td>6-Maleimidocaproic acid</td><td>/</td></tr><tr><td>C162115</td><td>ZW49</td><td>HER2</td><td>ZW25</td><td>N-acyl</td><td>Protease</td><td>2</td></tr><tr><td>C101524</td><td>TAK-264</td><td>GCC</td><td>Indusatumab</td><td>MMAE</td><td>VC</td><td>7.4</td></tr><tr><td>C156707</td><td>TAK-164</td><td>GCC</td><td>5F9</td><td>DGN549</td><td>Peptidic</td><td>/</td></tr><tr><td>[<xref ref-type="bibr" rid="CR150">150</xref>]</td><td>EV20/NMS-P945</td><td>HER3</td><td>EV20</td><td>NMS-P945</td><td>Peptidic</td><td>3.6</td></tr><tr><td>C136987</td><td>U3-1402</td><td>HER3</td><td>Patritumab</td><td>DXd</td><td>Tetrapeptide</td><td>8</td></tr><tr><td>C180413</td><td>CMG901</td><td>CLDN18.2</td><td>mAb</td><td>MMAE</td><td>Undisclosed</td><td>8</td></tr><tr><td>C190788</td><td>SOT102</td><td>CLDN18.2</td><td>IgG1 mAb</td><td>PNU-159682</td><td>Amide/peptide</td><td>2</td></tr><tr><td>C102783</td><td>IMMU-132</td><td>TROP2</td><td>hRS7</td><td>SN-38</td><td>CL2A</td><td>7.6</td></tr><tr><td>C166409</td><td>SKB264</td><td>TROP2</td><td>Sacituzumab</td><td>T030</td><td>CL2A</td><td>7.4</td></tr><tr><td>[<xref ref-type="bibr" rid="CR173">173</xref>]</td><td>Nectin-4 NDC</td><td>Nectin-4</td><td>Nb</td><td>MMAE</td><td>maleimide</td><td>1</td></tr></tbody></table><table-wrap-foot><p><italic>HER</italic> human epidermal growth factor receptor, <italic>TROP2</italic> trophoblast cell surface antigen 2, <italic>GCC</italic> Guanylate cyclase C, <italic>MMAE</italic> monomethyl auristatin E, <italic>MMAF</italic> monomethyl auristatin F, <italic>AF-HPA</italic> auristatin f-hydroxypropylamide, <italic>VC</italic> valine-citrulline, <italic>DM1</italic> mertansine, <italic>DXd</italic> deruxtecan, <italic>SMCC</italic> succinimidyl-4-(Nmaleimidomethyl) cyclohexane-1-carboxylate, <italic>pAcF</italic> para-acetyl-phenylalanine, <italic>IgG</italic> immunoglobulin G, <italic>NDC</italic> nanobody-drug conjugate, <italic>Nb</italic> nanobodies.</p></table-wrap-foot></table-wrap></p></sec></sec></sec><sec id="Sec37"><title>Conclusions and perspectives</title><p id="Par77">ADC therapy has emerged as a promising treatment option for cancer, with several foundational and early-phase clinical trials for digestive system tumors currently underway. These trials have highlighted the unique potential of ADCs in the treatment of GC. Nevertheless, the development of ADCs faces several challenges, including the complexity of the drug structure, targeted delivery, and associated toxic side effects.</p><p id="Par78">Key issues requiring urgent focus include overcoming drug resistance and understanding the mechanisms underlying antigenic expression heterogeneity. The continued research and development of ADCs must be underpinned by comprehensive clinical data and accurate disease classification to ensure their effective integration into clinical practice. Despite ongoing efforts, challenges persist, leading to suboptimal results in clinical trials, suggesting that significant progress is still needed to meet the original therapeutic objectives.</p><p id="Par79">Looking forward, the development of next-generation ADCs, particularly those utilizing recombinant drug strategies, is essential to enhance cancer cell targeting and lysosomal delivery. For example, antibodies conjugated with cell-penetrating peptides may improve ADC targeting and facilitate lysosomal internalization. Future ADC advancements will require the creation of more precise humanized mAbs, more potent cytotoxic payloads, stable, enzymatically cleavable linkers, and innovative coupling technologies. These innovations are expected to optimize therapeutic efficacy, minimize off-target toxicity, and broaden the clinical applications of ADCs. Additionally, emerging technologies, including alternatives to mAbs such as nanobodies and protein scaffolds, hold promise for advancing ADC development.</p><p id="Par80">Clinical and translational strategies are essential for expanding the therapeutic window of ADCs. Moreover, combination therapies have the potential to enhance ADC efficacy and mitigate resistance. With ongoing optimization and insights gained from two decades of clinical experience, the development of more efficient and safer ADCs for GC treatment is expected, ultimately leading to improved patient survival.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Qingling Yin collected relevant literature, prepared data, and drafted the manuscript. Yanlong Zhang participated in the summary and drawing of tables and pictures. Meijun Hou and Xunsheng Chen participated in the design of this review. Xueqing Xie and Jie Ding made strict revisions to the manuscript. All authors read and approve the final draft.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the National Natural Science Foundation of China (81360366, 81302169, 82360586); Guizhou Science and Technology Foundation ([2019]1198, [2020]1Z064).</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par81">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>EC</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Grabsch</surname><given-names>HI</given-names></name><name><surname>van Grieken</surname><given-names>NC</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name></person-group><article-title>Gastric cancer</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>635</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">32861308</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635&#x02013;48.<pub-id pub-id-type="pmid">32861308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>D'Amico</surname><given-names>TA</given-names></name><name><surname>Bentrem</surname><given-names>DJ</given-names></name><name><surname>Chao</surname><given-names>J</given-names></name><name><surname>Cooke</surname><given-names>D</given-names></name><name><surname>Corvera</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology</article-title><source>J Natl Compr Canc Netw</source><year>2022</year><volume>20</volume><fpage>167</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">35130500</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:167&#x02013;92.<pub-id pub-id-type="pmid">35130500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Kapesa</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name></person-group><article-title>Lauren classification and individualized chemotherapy in gastric cancer</article-title><source>Oncol Lett</source><year>2016</year><volume>11</volume><fpage>2959</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">27123046</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett 2016;11:2959&#x02013;64.<pub-id pub-id-type="pmid">27123046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JK</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Jin</surname><given-names>ZY</given-names></name><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>RQ</given-names></name><etal/></person-group><article-title>Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach</article-title><source>Eur J Cancer Prev</source><year>2017</year><volume>26</volume><fpage>357</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">27275735</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Zhao JK, Wu M, Kim CH, Jin ZY, Zhou JY, Han RQ, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach. Eur J Cancer Prev 2017;26:357&#x02013;64.<pub-id pub-id-type="pmid">27275735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Seo</surname><given-names>AN</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic Usefulness of p53 Immunostaining in Gastric Cancer and Dysplasia: A Real-world Clinical Experience</article-title><source>Vivo</source><year>2024</year><volume>38</volume><fpage>1865</fpage><lpage>74</lpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Park JH, Seo AN, Kim M. Diagnostic Usefulness of p53 Immunostaining in Gastric Cancer and Dysplasia: A Real-world Clinical Experience. Vivo. 2024;38:1865&#x02013;74.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Jabini</surname><given-names>R</given-names></name><name><surname>Eghbali</surname><given-names>SA</given-names></name><name><surname>Ayatollahi</surname><given-names>H</given-names></name><name><surname>Sheikhi</surname><given-names>M</given-names></name><name><surname>Farzanehfar</surname><given-names>M</given-names></name></person-group><article-title>Analysis of KRAS gene mutation associated with Helicobacter pylori infection in patients with gastric cancer</article-title><source>Iran J Basic Med Sci</source><year>2019</year><volume>22</volume><fpage>529</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">31217933</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Jabini R, Eghbali SA, Ayatollahi H, Sheikhi M, Farzanehfar M. Analysis of KRAS gene mutation associated with Helicobacter pylori infection in patients with gastric cancer. Iran J Basic Med Sci 2019;22:529&#x02013;33.<pub-id pub-id-type="pmid">31217933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>MK</given-names></name><name><surname>Jobe</surname><given-names>BA</given-names></name><name><surname>Luketich</surname><given-names>JD</given-names></name></person-group><article-title>Oesophageal carcinoma</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>400</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23374478</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400&#x02013;12.<pub-id pub-id-type="pmid">23374478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020</article-title><source>Cancer Commun (Lond)</source><year>2021</year><volume>41</volume><fpage>1037</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">34288593</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037&#x02013;48.<pub-id pub-id-type="pmid">34288593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Progress of gastric cancer surgery in the era of precision medicine</article-title><source>Int J Biol Sci</source><year>2021</year><volume>17</volume><fpage>1041</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33867827</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wang Y, Zhang L, Yang Y, Lu S, Chen H. Progress of gastric cancer surgery in the era of precision medicine. Int J Biol Sci 2021;17:1041&#x02013;9.<pub-id pub-id-type="pmid">33867827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title>Targeted engineering of medicinal chemistry for cancer therapy: recent advances and perspectives</article-title><source>Angew Chem Int Ed Engl</source><year>2021</year><volume>60</volume><fpage>5626</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">32096328</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chen W, Sun Z, Lu L. Targeted engineering of medicinal chemistry for cancer therapy: recent advances and perspectives. Angew Chem Int Ed Engl 2021;60:5626&#x02013;43.<pub-id pub-id-type="pmid">32096328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name></person-group><article-title>Clinical advances in targeting epigenetics for cancer therapy</article-title><source>Febs j</source><year>2022</year><volume>289</volume><fpage>1214</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">33545740</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. Febs j. 2022;289:1214&#x02013;39.<pub-id pub-id-type="pmid">33545740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Aldea</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>F</given-names></name><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name></person-group><article-title>Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><fpage>874</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">33811122</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discov. 2021;11:874&#x02013;99.<pub-id pub-id-type="pmid">33811122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakadate</surname><given-names>Y</given-names></name><name><surname>Kodera</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Shirasawa</surname><given-names>S</given-names></name><name><surname>Tachibana</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><etal/></person-group><article-title>KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><fpage>2146</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">24136682</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, et al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer. 2014;134:2146&#x02013;55.<pub-id pub-id-type="pmid">24136682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchikama</surname><given-names>K</given-names></name><name><surname>Anami</surname><given-names>Y</given-names></name><name><surname>Ha</surname><given-names>SYY</given-names></name><name><surname>Yamazaki</surname><given-names>CM</given-names></name></person-group><article-title>Exploring the next generation of antibody-drug conjugates</article-title><source>Nat Rev Clin Oncol</source><year>2024</year><volume>21</volume><fpage>203</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">38191923</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203&#x02013;23.<pub-id pub-id-type="pmid">38191923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasio</surname><given-names>MK</given-names></name><name><surname>Shuey</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>BA</given-names></name></person-group><article-title>Antibody-drug conjugates in gynecologic cancers</article-title><source>Curr Treat Options Oncol</source><year>2024</year><volume>25</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">38172449</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Anastasio MK, Shuey S, Davidson BA. Antibody-drug conjugates in gynecologic cancers. Curr Treat Options Oncol. 2024;25:1&#x02013;19.<pub-id pub-id-type="pmid">38172449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>P</given-names></name><name><surname>Carmagnani Pestana</surname><given-names>R</given-names></name><name><surname>Corti</surname><given-names>C</given-names></name><name><surname>Modi</surname><given-names>S</given-names></name><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies</article-title><source>CA Cancer J Clin</source><year>2022</year><volume>72</volume><fpage>165</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">34767258</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165&#x02013;82.<pub-id pub-id-type="pmid">34767258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Gauzy-Lazo</surname><given-names>L</given-names></name><name><surname>Sassoon</surname><given-names>I</given-names></name><name><surname>Brun</surname><given-names>MP</given-names></name></person-group><article-title>Advances in antibody-drug conjugate design: current clinical landscape and future innovations</article-title><source>SLAS Discov</source><year>2020</year><volume>25</volume><fpage>843</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">32192384</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gauzy-Lazo L, Sassoon I, Brun MP. Advances in antibody-drug conjugate design: current clinical landscape and future innovations. SLAS Discov. 2020;25:843&#x02013;68.<pub-id pub-id-type="pmid">32192384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Antibody drug conjugate: the &#x0201c;biological missile&#x0201d; for targeted cancer therapy</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><fpage>93</fpage><pub-id pub-id-type="pmid">35318309</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the &#x0201c;biological missile&#x0201d; for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.<pub-id pub-id-type="pmid">35318309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Steffenfauseweh</surname><given-names>H</given-names></name><name><surname>Rottsch&#x000e4;fer</surname><given-names>D</given-names></name><name><surname>Vishnevskiy</surname><given-names>YV</given-names></name><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Stammler</surname><given-names>HG</given-names></name><name><surname>Szczepanik</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Isolation of an Annulated 1,4-Distibabenzene Diradicaloid</article-title><source>Angew Chem Int Ed Engl</source><year>2023</year><volume>62</volume><fpage>e202216003</fpage><pub-id pub-id-type="pmid">36598396</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Steffenfauseweh H, Rottsch&#x000e4;fer D, Vishnevskiy YV, Neumann B, Stammler HG, Szczepanik DW, et al. Isolation of an Annulated 1,4-Distibabenzene Diradicaloid. Angew Chem Int Ed Engl. 2023;62:e202216003.<pub-id pub-id-type="pmid">36598396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Monoclonal Antibodies. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galassi</surname><given-names>C</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Immunogenic cell stress and death</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><fpage>487</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">35145297</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487&#x02013;500.<pub-id pub-id-type="pmid">35145297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdollahpour-Alitappeh</surname><given-names>M</given-names></name><name><surname>Lotfinia</surname><given-names>M</given-names></name><name><surname>Gharibi</surname><given-names>T</given-names></name><name><surname>Mardaneh</surname><given-names>J</given-names></name><name><surname>Farhadihosseinabadi</surname><given-names>B</given-names></name><name><surname>Larki</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>5628</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">30478951</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2019;234:5628&#x02013;42.<pub-id pub-id-type="pmid">30478951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>MR</given-names></name><name><surname>Masters</surname><given-names>E</given-names></name><name><surname>Pazeraitis</surname><given-names>D</given-names></name><name><surname>Perera</surname><given-names>RL</given-names></name><name><surname>Syrjanen</surname><given-names>JL</given-names></name><name><surname>Surade</surname><given-names>S</given-names></name><etal/></person-group><article-title>Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries</article-title><source>MAbs</source><year>2020</year><volume>12</volume><fpage>1829335</fpage><pub-id pub-id-type="pmid">33103593</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12:1829335.<pub-id pub-id-type="pmid">33103593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>EJ</given-names></name><name><surname>Reilly</surname><given-names>AF</given-names></name><name><surname>Lim</surname><given-names>MS</given-names></name><name><surname>Gross</surname><given-names>TG</given-names></name><name><surname>Saguilig</surname><given-names>L</given-names></name><name><surname>Barkauskas</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1</article-title><source>Blood</source><year>2021</year><volume>137</volume><fpage>3595</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">33684925</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595&#x02013;603.<pub-id pub-id-type="pmid">33684925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name></person-group><article-title>How to select IgG subclasses in developing anti-tumor therapeutic antibodies</article-title><source>J Hematol Oncol</source><year>2020</year><volume>13</volume><fpage>45</fpage><pub-id pub-id-type="pmid">32370812</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13:45.<pub-id pub-id-type="pmid">32370812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Sawant</surname><given-names>MS</given-names></name><name><surname>Streu</surname><given-names>CN</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Tessier</surname><given-names>PM</given-names></name></person-group><article-title>Toward drug-like multispecific antibodies by design</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7496.</fpage><pub-id pub-id-type="pmid">33053650</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Sawant MS, Streu CN, Wu L, Tessier PM. Toward drug-like multispecific antibodies by design. Int J Mol Sci. 2020;21:7496.<pub-id pub-id-type="pmid">33053650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>TH</given-names></name><name><surname>Jung</surname><given-names>ST</given-names></name></person-group><article-title>Boosting therapeutic potency of antibodies by taming Fc domain functions</article-title><source>Exp Mol Med</source><year>2019</year><volume>51</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31811117</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp Mol Med. 2019;51:1&#x02013;9.<pub-id pub-id-type="pmid">31811117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>MacTaggart</surname><given-names>B</given-names></name><name><surname>Kashina</surname><given-names>A</given-names></name></person-group><article-title>Posttranslational modifications of the cytoskeleton</article-title><source>Cytoskeleton (Hoboken)</source><year>2021</year><volume>78</volume><fpage>142</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">34152688</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">MacTaggart B, Kashina A. Posttranslational modifications of the cytoskeleton. Cytoskeleton (Hoboken). 2021;78:142&#x02013;73.<pub-id pub-id-type="pmid">34152688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name></person-group><article-title>Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates</article-title><source>Pharm Res</source><year>2015</year><volume>32</volume><fpage>3577</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">26108878</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xu S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm Res. 2015;32:3577&#x02013;83.<pub-id pub-id-type="pmid">26108878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Schladetsch</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Balunas</surname><given-names>MJ</given-names></name><name><surname>Wiemer</surname><given-names>AJ</given-names></name></person-group><article-title>Stepping forward in antibody-drug conjugate development</article-title><source>Pharm Ther</source><year>2022</year><volume>229</volume><fpage>107917</fpage></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharm Ther. 2022;229:107917.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Emmerton</surname><given-names>KK</given-names></name><name><surname>Jonas</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Miyamoto</surname><given-names>JB</given-names></name><name><surname>Setter</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>2710</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26921341</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710&#x02013;9.<pub-id pub-id-type="pmid">26921341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sheyi</surname><given-names>R</given-names></name><name><surname>de la Torre</surname><given-names>BG</given-names></name><name><surname>Albericio</surname><given-names>F</given-names></name></person-group><article-title>Linkers: an assurance for controlled delivery of antibody-drug conjugate</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>396.</fpage><pub-id pub-id-type="pmid">35214128</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. 2022;14:396.<pub-id pub-id-type="pmid">35214128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Bargh</surname><given-names>JD</given-names></name><name><surname>Isidro-Llobet</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Spring</surname><given-names>DR</given-names></name></person-group><article-title>Cleavable linkers in antibody-drug conjugates</article-title><source>Chem Soc Rev</source><year>2019</year><volume>48</volume><fpage>4361</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">31294429</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48:4361&#x02013;74.<pub-id pub-id-type="pmid">31294429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antibody-drug conjugates: Recent advances in linker chemistry</article-title><source>Acta Pharm Sin B</source><year>2021</year><volume>11</volume><fpage>3889</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">35024314</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021;11:3889&#x02013;907.<pub-id pub-id-type="pmid">35024314</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>The analysis of key factors related to ADCs structural design</article-title><source>Front Pharm</source><year>2019</year><volume>10</volume><fpage>373</fpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, et al. The analysis of key factors related to ADCs structural design. Front Pharm. 2019;10:373.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Marm&#x000e9;</surname><given-names>F</given-names></name></person-group><article-title>Antibody-drug conjugates for breast cancer</article-title><source>Oncol Res Treat</source><year>2022</year><volume>45</volume><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">34915488</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Marm&#x000e9; F. Antibody-drug conjugates for breast cancer. Oncol Res Treat. 2022;45:26&#x02013;36.<pub-id pub-id-type="pmid">34915488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>WT</given-names></name><name><surname>Marks</surname><given-names>PW</given-names></name></person-group><article-title>Gemtuzumab ozogamicin: is there room for salvage?</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>2618</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20930085</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood. 2010;116:2618&#x02013;9.<pub-id pub-id-type="pmid">20930085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>SF</given-names></name><name><surname>Del Rosario</surname><given-names>G</given-names></name><name><surname>Leong</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>GY</given-names></name><name><surname>Vij</surname><given-names>R</given-names></name><etal/></person-group><article-title>An Anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><fpage>1358</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">29959143</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, et al. An Anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res. 2019;25:1358&#x02013;68.<pub-id pub-id-type="pmid">29959143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy</article-title><source>Drug Deliv</source><year>2022</year><volume>29</volume><fpage>1764</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">35638851</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zheng S, Cai Y, Hong Y, Gong Y, Gao L, Li Q, et al. Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy. Drug Deliv. 2022;29:1764&#x02013;75.<pub-id pub-id-type="pmid">35638851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>RM</given-names></name><name><surname>Mele</surname><given-names>S</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Larcombe-Young</surname><given-names>D</given-names></name><name><surname>Bucaite</surname><given-names>G</given-names></name><name><surname>Sachouli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)</article-title><source>Sci Rep.</source><year>2020</year><volume>10</volume><fpage>8869</fpage><pub-id pub-id-type="pmid">32483228</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hoffmann RM, Mele S, Cheung A, Larcombe-Young D, Bucaite G, Sachouli E, et al. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). Sci Rep. 2020;10:8869.<pub-id pub-id-type="pmid">32483228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>G</given-names></name><name><surname>Attah</surname><given-names>IK</given-names></name><name><surname>Conant</surname><given-names>CR</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Garimella</surname><given-names>SVB</given-names></name><name><surname>Gunawardena</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Rapid and simultaneous characterization of drug conjugation in heavy and light chains of a monoclonal antibody revealed by high-resolution ion mobility separations in SLIM</article-title><source>Anal Chem</source><year>2020</year><volume>92</volume><fpage>5004</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">32142606</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Nagy G, Attah IK, Conant CR, Liu W, Garimella SVB, Gunawardena HP, et al. Rapid and simultaneous characterization of drug conjugation in heavy and light chains of a monoclonal antibody revealed by high-resolution ion mobility separations in SLIM. Anal Chem. 2020;92:5004&#x02013;12.<pub-id pub-id-type="pmid">32142606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ponte</surname><given-names>JF</given-names></name><name><surname>Yoder</surname><given-names>NC</given-names></name><name><surname>Laleau</surname><given-names>R</given-names></name><name><surname>Coccia</surname><given-names>J</given-names></name><name><surname>Lanieri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates</article-title><source>Bioconjug Chem</source><year>2017</year><volume>28</volume><fpage>1371</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">28388844</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, et al. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 2017;28:1371&#x02013;81.<pub-id pub-id-type="pmid">28388844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Saber</surname><given-names>H</given-names></name><name><surname>Simpson</surname><given-names>N</given-names></name><name><surname>Ricks</surname><given-names>TK</given-names></name><name><surname>Leighton</surname><given-names>JK</given-names></name></person-group><article-title>An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates</article-title><source>Regul Toxicol Pharm</source><year>2019</year><volume>107</volume><fpage>104429</fpage></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Saber H, Simpson N, Ricks TK, Leighton JK. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. Regul Toxicol Pharm. 2019;107:104429.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>P</given-names></name><name><surname>Phipps</surname><given-names>C</given-names></name><name><surname>Edginton</surname><given-names>A</given-names></name><name><surname>Blay</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetic considerations for antibody-drug conjugates against cancer</article-title><source>Pharm Res</source><year>2017</year><volume>34</volume><fpage>2579</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">28924691</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Malik P, Phipps C, Edginton A, Blay J. Pharmacokinetic considerations for antibody-drug conjugates against cancer. Pharm Res. 2017;34:2579&#x02013;95.<pub-id pub-id-type="pmid">28924691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>S</given-names></name><name><surname>Haag</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name></person-group><article-title>An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer</article-title><source>J Control Release</source><year>2021</year><volume>340</volume><fpage>331</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">34774889</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Zhang Y, Yue S, Haag R, Sun H, Zhong Z. An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer. J Control Release. 2021;340:331&#x02013;41.<pub-id pub-id-type="pmid">34774889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>N</given-names></name><name><surname>Setua</surname><given-names>S</given-names></name><name><surname>Kashyap</surname><given-names>VK</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Jaggi</surname><given-names>M</given-names></name><name><surname>Yallapu</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Antibody-drug conjugates for cancer therapy: chemistry to clinical implications</article-title><source>Pharmaceuticals (Basel)</source><year>2018</year><volume>11</volume><fpage>32.</fpage><pub-id pub-id-type="pmid">29642542</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, et al. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). 2018;11:32.<pub-id pub-id-type="pmid">29642542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrling</surname><given-names>T</given-names></name><name><surname>Soltis</surname><given-names>D</given-names></name></person-group><article-title>Challenges in optimising the successful construction of antibody drug conjugates in cancer therapy</article-title><source>Antibodies (Basel)</source><year>2018</year><volume>7</volume><fpage>11.</fpage><pub-id pub-id-type="pmid">31544863</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Mehrling T, Soltis D. Challenges in optimising the successful construction of antibody drug conjugates in cancer therapy. Antibodies (Basel). 2018;7:11.<pub-id pub-id-type="pmid">31544863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Moore</surname><given-names>KN</given-names></name><name><surname>Betella</surname><given-names>I</given-names></name><name><surname>Bates</surname><given-names>RC</given-names></name></person-group><article-title>Antibody-drug conjugate-based therapeutics: state of the science</article-title><source>J Natl Cancer Inst</source><year>2019</year><volume>111</volume><fpage>538</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">30859213</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538&#x02013;49.<pub-id pub-id-type="pmid">30859213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name></person-group><article-title>Current analytical strategies for antibody-drug conjugates in biomatrices</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>6299.</fpage><pub-id pub-id-type="pmid">36234836</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Qin Q, Gong L. Current analytical strategies for antibody-drug conjugates in biomatrices. Molecules. 2022;27:6299.<pub-id pub-id-type="pmid">36234836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>JC</given-names></name><name><surname>Dooney</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Brandish</surname><given-names>PE</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Novel phosphate modified cathepsin B linkers: improving aqueous solubility and enhancing payload scope of ADCs</article-title><source>Bioconjug Chem</source><year>2016</year><volume>27</volume><fpage>2081</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27469406</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kern JC, Dooney D, Zhang R, Liang L, Brandish PE, Cheng M, et al. Novel phosphate modified cathepsin B linkers: improving aqueous solubility and enhancing payload scope of ADCs. Bioconjug Chem. 2016;27:2081&#x02013;8.<pub-id pub-id-type="pmid">27469406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalingaiah</surname><given-names>PK</given-names></name><name><surname>Ciurlionis</surname><given-names>R</given-names></name><name><surname>Durbin</surname><given-names>KR</given-names></name><name><surname>Yeager</surname><given-names>RL</given-names></name><name><surname>Philip</surname><given-names>BK</given-names></name><name><surname>Bawa</surname><given-names>B</given-names></name><etal/></person-group><article-title>Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates</article-title><source>Pharm Ther</source><year>2019</year><volume>200</volume><fpage>110</fpage><lpage>25</lpage></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharm Ther. 2019;200:110&#x02013;25.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e4;ger</surname><given-names>S</given-names></name><name><surname>Dickgiesser</surname><given-names>S</given-names></name><name><surname>Tonillo</surname><given-names>J</given-names></name><name><surname>Hecht</surname><given-names>S</given-names></name><name><surname>Kolmar</surname><given-names>H</given-names></name><name><surname>Schr&#x000f6;ter</surname><given-names>C</given-names></name></person-group><article-title>EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing</article-title><source>Biol Chem</source><year>2022</year><volume>403</volume><fpage>525</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">34535048</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">J&#x000e4;ger S, Dickgiesser S, Tonillo J, Hecht S, Kolmar H, Schr&#x000f6;ter C. EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing. Biol Chem. 2022;403:525&#x02013;34.<pub-id pub-id-type="pmid">34535048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita-Kashima</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>S</given-names></name><name><surname>Osada</surname><given-names>M</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Yoshiura</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><etal/></person-group><article-title>Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation</article-title><source>Cancer Chemother Pharm</source><year>2020</year><volume>86</volume><fpage>641</fpage><lpage>54</lpage></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yamashita-Kashima Y, Shu S, Osada M, Fujimura T, Yoshiura S, Harada N, et al. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation. Cancer Chemother Pharm. 2020;86:641&#x02013;54.</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Loganzo</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Sung</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>JS</given-names></name><name><surname>Melamud</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments</article-title><source>Mol Cancer Ther</source><year>2015</year><volume>14</volume><fpage>952</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">25646013</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14:952&#x02013;63.<pub-id pub-id-type="pmid">25646013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Le Joncour</surname><given-names>V</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Puhka</surname><given-names>M</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Salmikangas</surname><given-names>M</given-names></name><name><surname>Laakkonen</surname><given-names>P</given-names></name><etal/></person-group><article-title>A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine</article-title><source>Mol Cancer Ther</source><year>2019</year><volume>18</volume><fpage>1721</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">31292166</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, et al. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Mol Cancer Ther. 2019;18:1721&#x02013;30.<pub-id pub-id-type="pmid">31292166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>R</given-names></name><name><surname>Saleh</surname><given-names>K</given-names></name><name><surname>Khalife</surname><given-names>N</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Chahine</surname><given-names>C</given-names></name><name><surname>Ibrahim</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mechanisms of resistance to antibody-drug conjugates</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>9674.</fpage><pub-id pub-id-type="pmid">37298631</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24:9674.<pub-id pub-id-type="pmid">37298631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>M</given-names></name><name><surname>Tchistiakova</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name></person-group><article-title>Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates</article-title><source>MAbs</source><year>2013</year><volume>5</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">23221464</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5:13&#x02013;21.<pub-id pub-id-type="pmid">23221464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000ed;os-Luci</surname><given-names>C</given-names></name><name><surname>Garc&#x000ed;a-Alonso</surname><given-names>S</given-names></name><name><surname>D&#x000ed;az-Rodr&#x000ed;guez</surname><given-names>E</given-names></name><name><surname>Nadal-Serrano</surname><given-names>M</given-names></name><name><surname>Arribas</surname><given-names>J</given-names></name><name><surname>Oca&#x000f1;a</surname><given-names>A</given-names></name><etal/></person-group><article-title>Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><fpage>4639</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28687619</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">R&#x000ed;os-Luci C, Garc&#x000ed;a-Alonso S, D&#x000ed;az-Rodr&#x000ed;guez E, Nadal-Serrano M, Arribas J, Oca&#x000f1;a A, et al. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Res. 2017;77:4639&#x02013;51.<pub-id pub-id-type="pmid">28687619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>You</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Autophagy in cancer development, immune evasion, and drug resistance</article-title><source>Drug Resist Updat</source><year>2025</year><volume>78</volume><fpage>101170</fpage><pub-id pub-id-type="pmid">39603146</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Niu X, You Q, Hou K, Tian Y, Wei P, Zhu Y, et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist Updat. 2025;78:101170.<pub-id pub-id-type="pmid">39603146</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Ashrafizadeh</surname><given-names>M</given-names></name><name><surname>Mongiardini</surname><given-names>V</given-names></name><name><surname>Grimaldi</surname><given-names>B</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Rietdorf</surname><given-names>K</given-names></name><etal/></person-group><article-title>Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence</article-title><source>Cancer Lett</source><year>2023</year><volume>570</volume><fpage>216307</fpage><pub-id pub-id-type="pmid">37451426</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, et al. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence. Cancer Lett. 2023;570:216307.<pub-id pub-id-type="pmid">37451426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Zamame Ramirez</surname><given-names>JA</given-names></name><name><surname>Romagnoli</surname><given-names>GG</given-names></name><name><surname>Kaneno</surname><given-names>R</given-names></name></person-group><article-title>Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy</article-title><source>Life Sci</source><year>2021</year><volume>265</volume><fpage>118745</fpage><pub-id pub-id-type="pmid">33186569</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Zamame Ramirez JA, Romagnoli GG, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci. 2021;265:118745.<pub-id pub-id-type="pmid">33186569</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Nan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer</article-title><source>Cell Death Discov</source><year>2024</year><volume>10</volume><fpage>393</fpage><pub-id pub-id-type="pmid">39227365</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Xue W, Xu C, Zhang K, Cui L, Huang X, Nan Y, et al. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. Cell Death Discov. 2024;10:393.<pub-id pub-id-type="pmid">39227365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>El Rouby</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Silber</surname><given-names>R</given-names></name><name><surname>Potmesil</surname><given-names>M</given-names></name><etal/></person-group><article-title>Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance</article-title><source>Oncogene</source><year>1996</year><volume>12</volume><fpage>1055</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8649796</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12:1055&#x02013;62.<pub-id pub-id-type="pmid">8649796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbaghi</surname><given-names>M</given-names></name><name><surname>Gil-G&#x000f3;mez</surname><given-names>G</given-names></name><name><surname>Guardia</surname><given-names>C</given-names></name><name><surname>Servitja</surname><given-names>S</given-names></name><name><surname>Arp&#x000ed;</surname><given-names>O</given-names></name><name><surname>Garc&#x000ed;a-Alonso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>7006</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">28821558</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Sabbaghi M, Gil-G&#x000f3;mez G, Guardia C, Servitja S, Arp&#x000ed; O, Garc&#x000ed;a-Alonso S, et al. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clin Cancer Res. 2017;23:7006&#x02013;19.<pub-id pub-id-type="pmid">28821558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Perry</surname><given-names>SR</given-names></name><name><surname>Muniz-Medina</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wetzel</surname><given-names>LK</given-names></name><name><surname>Rebelatto</surname><given-names>MC</given-names></name><etal/></person-group><article-title>A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</article-title><source>Cancer Cell</source><year>2016</year><volume>29</volume><fpage>117</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">26766593</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117&#x02013;29.<pub-id pub-id-type="pmid">26766593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Perry</surname><given-names>SR</given-names></name><name><surname>Muniz-Medina</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wetzel</surname><given-names>LK</given-names></name><name><surname>Rebelatto</surname><given-names>MC</given-names></name><etal/></person-group><article-title>A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><fpage>948</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31185215</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2019;35:948&#x02013;9.<pub-id pub-id-type="pmid">31185215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreev</surname><given-names>J</given-names></name><name><surname>Thambi</surname><given-names>N</given-names></name><name><surname>Perez Bay</surname><given-names>AE</given-names></name><name><surname>Delfino</surname><given-names>F</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs</article-title><source>Mol Cancer Ther</source><year>2017</year><volume>16</volume><fpage>681</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">28108597</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16:681&#x02013;93.<pub-id pub-id-type="pmid">28108597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Rios-Doria</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>J</given-names></name><name><surname>Rothstein</surname><given-names>R</given-names></name><name><surname>Wetzel</surname><given-names>L</given-names></name><name><surname>Chesebrough</surname><given-names>J</given-names></name><name><surname>Marrero</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><fpage>2686</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">28283653</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, et al. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 2017;77:2686&#x02013;98.<pub-id pub-id-type="pmid">28283653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauzon</surname><given-names>M</given-names></name><name><surname>Drake</surname><given-names>PM</given-names></name><name><surname>Barfield</surname><given-names>RM</given-names></name><name><surname>Cornali</surname><given-names>BM</given-names></name><name><surname>Rupniewski</surname><given-names>I</given-names></name><name><surname>Rabuka</surname><given-names>D</given-names></name></person-group><article-title>Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><fpage>e1565859</fpage><pub-id pub-id-type="pmid">30906660</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Bauzon M, Drake PM, Barfield RM, Cornali BM, Rupniewski I, Rabuka D. Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology. 2019;8:e1565859.<pub-id pub-id-type="pmid">30906660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Setiady</surname><given-names>YY</given-names></name><name><surname>Ponte</surname><given-names>J</given-names></name><name><surname>Kovtun</surname><given-names>YV</given-names></name><name><surname>Lai</surname><given-names>KC</given-names></name><name><surname>Hong</surname><given-names>EE</given-names></name><etal/></person-group><article-title>A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells</article-title><source>Mol Cancer Ther</source><year>2016</year><volume>15</volume><fpage>1311</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">27197308</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, et al. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. Mol Cancer Ther. 2016;15:1311&#x02013;20.<pub-id pub-id-type="pmid">27197308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Manibusan</surname><given-names>A</given-names></name><name><surname>Sellers</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A general approach to site-specific antibody drug conjugates</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>1766</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24443552</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci USA. 2014;111:1766&#x02013;71.<pub-id pub-id-type="pmid">24443552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>IM</given-names></name><name><surname>Okines</surname><given-names>AFC</given-names></name></person-group><article-title>Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><fpage>2259.</fpage><pub-id pub-id-type="pmid">38927964</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Browne IM, Okines AFC. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers (Basel). 2024;16:2259.<pub-id pub-id-type="pmid">38927964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer</article-title><source>Cancer Lett</source><year>2024</year><volume>598</volume><fpage>217112</fpage><pub-id pub-id-type="pmid">38986734</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Zhang H, Zhang L, He Y, Jiang D, Sun J, Luo Q, et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 2024;598:217112.<pub-id pub-id-type="pmid">38986734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nan</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><fpage>293</fpage><pub-id pub-id-type="pmid">38664366</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang X, et al. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death Dis. 2024;15:293.<pub-id pub-id-type="pmid">38664366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Nan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Activating autophagy enhanced the antitumor effect of antibody drug conjugates rituximab-monomethyl auristatin E</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1799</fpage><pub-id pub-id-type="pmid">30123222</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wang Y, Zhang X, Fan J, Chen W, Luan J, Nan Y, et al. Activating autophagy enhanced the antitumor effect of antibody drug conjugates rituximab-monomethyl auristatin E. Front Immunol. 2018;9:1799.<pub-id pub-id-type="pmid">30123222</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Czechowicz</surname><given-names>A</given-names></name><name><surname>Palchaudhuri</surname><given-names>R</given-names></name><name><surname>Scheck</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Hoggatt</surname><given-names>J</given-names></name><name><surname>Saez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>617</fpage><pub-id pub-id-type="pmid">30728354</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun 2019;10:617.<pub-id pub-id-type="pmid">30728354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>SYY</given-names></name><name><surname>Anami</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>CM</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Haase</surname><given-names>CM</given-names></name><name><surname>Olson</surname><given-names>SD</given-names></name><etal/></person-group><article-title>An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates</article-title><source>Mol Cancer Ther</source><year>2022</year><volume>21</volume><fpage>1449</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">35793453</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Ha SYY, Anami Y, Yamazaki CM, Xiong W, Haase CM, Olson SD, et al. An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates. Mol Cancer Ther. 2022;21:1449&#x02013;61.<pub-id pub-id-type="pmid">35793453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Neff-LaFord</surname><given-names>HD</given-names></name><name><surname>Carratt</surname><given-names>SA</given-names></name><name><surname>Carosino</surname><given-names>C</given-names></name><name><surname>Everds</surname><given-names>N</given-names></name><name><surname>Cardinal</surname><given-names>KA</given-names></name><name><surname>Duniho</surname><given-names>S</given-names></name><etal/></person-group><article-title>The vedotin antibody-drug conjugate payload drives platform-based nonclinical safety and pharmacokinetic profiles</article-title><source>Mol Cancer Ther</source><year>2024</year><volume>23</volume><fpage>1483</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">38692647</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Neff-LaFord HD, Carratt SA, Carosino C, Everds N, Cardinal KA, Duniho S, et al. The vedotin antibody-drug conjugate payload drives platform-based nonclinical safety and pharmacokinetic profiles. Mol Cancer Ther. 2024;23:1483&#x02013;93.<pub-id pub-id-type="pmid">38692647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Bordeau</surname><given-names>BM</given-names></name><name><surname>Balthasar</surname><given-names>JP</given-names></name></person-group><article-title>Mechanisms of ADC toxicity and strategies to increase ADC tolerability</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><fpage>713.</fpage><pub-id pub-id-type="pmid">36765668</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713.<pub-id pub-id-type="pmid">36765668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Modi</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Murthy</surname><given-names>RK</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Tsurutani</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antitumor activity and safety of trastuzumab deruxtecan in patients With HER2-low-expressing advanced breast cancer: results from a phase Ib Study</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>1887</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">32058843</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients With HER2-low-expressing advanced breast cancer: results from a phase Ib Study. J Clin Oncol. 2020;38:1887&#x02013;96.<pub-id pub-id-type="pmid">32058843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Ogitani</surname><given-names>Y</given-names></name><name><surname>Hagihara</surname><given-names>K</given-names></name><name><surname>Oitate</surname><given-names>M</given-names></name><name><surname>Naito</surname><given-names>H</given-names></name><name><surname>Agatsuma</surname><given-names>T</given-names></name></person-group><article-title>Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</article-title><source>Cancer Sci</source><year>2016</year><volume>107</volume><fpage>1039</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">27166974</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039&#x02013;46.<pub-id pub-id-type="pmid">27166974</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Strop</surname><given-names>P</given-names></name><name><surname>Tran</surname><given-names>TT</given-names></name><name><surname>Dorywalska</surname><given-names>M</given-names></name><name><surname>Delaria</surname><given-names>K</given-names></name><name><surname>Dushin</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>OK</given-names></name><etal/></person-group><article-title>RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models</article-title><source>Mol Cancer Ther</source><year>2016</year><volume>15</volume><fpage>2698</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">27582525</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, et al. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Mol Cancer Ther. 2016;15:2698&#x02013;708.<pub-id pub-id-type="pmid">27582525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Conilh</surname><given-names>L</given-names></name><name><surname>Sadilkova</surname><given-names>L</given-names></name><name><surname>Viricel</surname><given-names>W</given-names></name><name><surname>Dumontet</surname><given-names>C</given-names></name></person-group><article-title>Payload diversification: a key step in the development of antibody-drug conjugates</article-title><source>J Hematol Oncol</source><year>2023</year><volume>16</volume><fpage>3</fpage><pub-id pub-id-type="pmid">36650546</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16:3.<pub-id pub-id-type="pmid">36650546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name></person-group><article-title>Tumor site-specific cleavage improves the antitumor efficacy of antibody-drug conjugates</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>11011.</fpage><pub-id pub-id-type="pmid">37446189</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Xu K, Han J, Yang L, Cao L, Li S, Hong Z. Tumor site-specific cleavage improves the antitumor efficacy of antibody-drug conjugates. Int J Mol Sci. 2023;24:11011.<pub-id pub-id-type="pmid">37446189</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Michot</surname><given-names>JM</given-names></name><name><surname>Bigenwald</surname><given-names>C</given-names></name><name><surname>Champiat</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Carbonnel</surname><given-names>F</given-names></name><name><surname>Postel-Vinay</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune-related adverse events with immune checkpoint blockade: a comprehensive review</article-title><source>Eur J Cancer</source><year>2016</year><volume>54</volume><fpage>139</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">26765102</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139&#x02013;48.<pub-id pub-id-type="pmid">26765102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Bechtold-Peters</surname><given-names>K</given-names></name><name><surname>Ruggiero</surname><given-names>A</given-names></name><name><surname>Vriezen</surname><given-names>N</given-names></name><name><surname>Ihle</surname><given-names>N</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><etal/></person-group><article-title>CMC regulatory considerations for antibody-drug conjugates</article-title><source>J Pharm Sci</source><year>2023</year><volume>112</volume><fpage>2965</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">37741455</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Bechtold-Peters K, Ruggiero A, Vriezen N, Ihle N, Klein A, Morgan C, et al. CMC regulatory considerations for antibody-drug conjugates. J Pharm Sci. 2023;112:2965&#x02013;80.<pub-id pub-id-type="pmid">37741455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Tumey</surname><given-names>LN</given-names></name></person-group><article-title>An overview of the current ADC discovery landscape</article-title><source>Methods Mol Biol</source><year>2020</year><volume>2078</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">31643046</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Tumey LN. An overview of the current ADC discovery landscape. Methods Mol Biol. 2020;2078:1&#x02013;22.<pub-id pub-id-type="pmid">31643046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Mumtaz</surname><given-names>T</given-names></name></person-group><article-title>Membranes and transport mechanisms</article-title><source>Pak J Health Sci</source><year>2022</year><volume>3</volume><fpage>02</fpage></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Mumtaz T. Membranes and transport mechanisms. Pak J Health Sci. 2022;3:02.</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi&#x000f2;</surname><given-names>C</given-names></name><name><surname>Annaratone</surname><given-names>L</given-names></name><name><surname>Marques</surname><given-names>A</given-names></name><name><surname>Casorzo</surname><given-names>L</given-names></name><name><surname>Berrino</surname><given-names>E</given-names></name><name><surname>Sapino</surname><given-names>A</given-names></name></person-group><article-title>Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond</article-title><source>Semin Cancer Biol</source><year>2021</year><volume>72</volume><fpage>123</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">32112814</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Marchi&#x000f2; C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123&#x02013;35.<pub-id pub-id-type="pmid">32112814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review</article-title><source>Med (Baltim)</source><year>2024</year><volume>103</volume><fpage>e38508</fpage></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X, et al. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. Med (Baltim). 2024;103:e38508.</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>DM</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Significant function and research progress of biomarkers in gastric cancer</article-title><source>Oncol Lett</source><year>2020</year><volume>19</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">31897111</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Ye DM, Xu G, Ma W, Li Y, Luo W, Xiao Y, et al. Significant function and research progress of biomarkers in gastric cancer. Oncol Lett. 2020;19:17&#x02013;29.<pub-id pub-id-type="pmid">31897111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimozaki</surname><given-names>K</given-names></name><name><surname>Fukuoka</surname><given-names>S</given-names></name><name><surname>Ooki</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name></person-group><article-title>HER2-low gastric cancer: is the subgroup targetable?</article-title><source>ESMO Open</source><year>2024</year><volume>9</volume><fpage>103679</fpage><pub-id pub-id-type="pmid">39178538</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Shimozaki K, Fukuoka S, Ooki A, Yamaguchi K. HER2-low gastric cancer: is the subgroup targetable? ESMO Open. 2024;9:103679.<pub-id pub-id-type="pmid">39178538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Miricescu</surname><given-names>D</given-names></name><name><surname>Totan</surname><given-names>A</given-names></name><name><surname>Stanescu</surname><given-names>S</given-names><suffix>II</suffix></name><name><surname>Badoiu</surname><given-names>SC</given-names></name><name><surname>Stefani</surname><given-names>C</given-names></name><name><surname>Greabu</surname><given-names>M</given-names></name></person-group><article-title>PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects</article-title><source>Int J Mol Sci</source><year>2020</year><volume>22</volume><fpage>173.</fpage><pub-id pub-id-type="pmid">33375317</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Miricescu D, Totan A, Stanescu S, II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22:173.<pub-id pub-id-type="pmid">33375317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000ed;az-Serrano</surname><given-names>A</given-names></name><name><surname>Angulo</surname><given-names>B</given-names></name><name><surname>Dominguez</surname><given-names>C</given-names></name><name><surname>Pazo-Cid</surname><given-names>R</given-names></name><name><surname>Salud</surname><given-names>A</given-names></name><name><surname>Jim&#x000e9;nez-Fonseca</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab</article-title><source>Oncologist</source><year>2018</year><volume>23</volume><fpage>1092</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">29700210</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">D&#x000ed;az-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jim&#x000e9;nez-Fonseca P, et al. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. Oncologist. 2018;23:1092&#x02013;102.<pub-id pub-id-type="pmid">29700210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshizawa</surname><given-names>R</given-names></name><name><surname>Umeki</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Sako</surname><given-names>Y</given-names></name></person-group><article-title>Biphasic spatiotemporal regulation of GRB2 dynamics by p52SHC for transient RAS activation</article-title><source>Biophys Physicobiol</source><year>2021</year><volume>18</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">33665062</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Yoshizawa R, Umeki N, Yamamoto A, Murata M, Sako Y. Biphasic spatiotemporal regulation of GRB2 dynamics by p52SHC for transient RAS activation. Biophys Physicobiol. 2021;18:1&#x02013;12.<pub-id pub-id-type="pmid">33665062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>CC</given-names></name></person-group><article-title>Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway</article-title><source>Int J Mol Med</source><year>2018</year><volume>41</volume><fpage>2389</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">29393362</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Su CC. Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway. Int J Mol Med. 2018;41:2389&#x02013;96.<pub-id pub-id-type="pmid">29393362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer</article-title><source>Int J Oncol</source><year>2016</year><volume>49</volume><fpage>1360</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27499357</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu Z, et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016;49:1360&#x02013;8.<pub-id pub-id-type="pmid">27499357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>G</given-names></name><name><surname>Seno</surname><given-names>M</given-names></name></person-group><article-title>ERBB signaling pathway in cancer stem cells</article-title><source>Adv Exp Med Biol</source><year>2022</year><volume>1393</volume><fpage>65</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">36587302</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Hassan G, Seno M. ERBB signaling pathway in cancer stem cells. Adv Exp Med Biol. 2022;1393:65&#x02013;81.<pub-id pub-id-type="pmid">36587302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Roskoski</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>Src kinase regulation by phosphorylation and dephosphorylation</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>331</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15845350</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005;331:1&#x02013;14.<pub-id pub-id-type="pmid">15845350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Guk</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>MH</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>6428</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">30317579</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Seo J, Guk G, Park SH, Jeong MH, Jeong JH, Yoon HG, et al. Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells. J Cell Physiol. 2019;234:6428&#x02013;36.<pub-id pub-id-type="pmid">30317579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Ouyang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells</article-title><source>Acta Biochim Biophys Sin (Shanghai)</source><year>2011</year><volume>43</volume><fpage>647</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21712253</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, et al. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011;43:647&#x02013;53.<pub-id pub-id-type="pmid">21712253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name></person-group><article-title>Label-free quantitative proteomics combined with biological validation reveals activation of Wnt/&#x003b2;-catenin pathway contributing to trastuzumab resistance in gastric cancer</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><fpage>1981.</fpage><pub-id pub-id-type="pmid">29986466</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Liu W, Yuan J, Liu Z, Zhang J, Chang J. Label-free quantitative proteomics combined with biological validation reveals activation of Wnt/&#x003b2;-catenin pathway contributing to trastuzumab resistance in gastric cancer. Int J Mol Sci. 2018;19:1981.<pub-id pub-id-type="pmid">29986466</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Bae</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Jung</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Wnt/&#x003b2;-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><fpage>922</fpage><pub-id pub-id-type="pmid">37773114</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kim Y, Bae YJ, Kim JH, Kim H, Shin SJ, Jung DH, et al. Wnt/&#x003b2;-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells. BMC Cancer. 2023;23:922.<pub-id pub-id-type="pmid">37773114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer</article-title><source>IUBMB Life</source><year>2024</year><volume>76</volume><fpage>420</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">38126920</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Jiang L, Zhao X, Li Y, Hu Y, Sun Y, Liu S, et al. The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer. IUBMB Life. 2024;76:420&#x02013;36.<pub-id pub-id-type="pmid">38126920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><fpage>21905</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">38050871</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Jing X, Luo Z, Wu J, Ye F, Li J, Song Z, et al. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression. Cancer Med. 2023;12:21905&#x02013;19.<pub-id pub-id-type="pmid">38050871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Lote</surname><given-names>H</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name></person-group><article-title>Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials</article-title><source>Expert Opin Investig Drugs</source><year>2022</year><volume>31</volume><fpage>59</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">35034511</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Lote H, Chau I. Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials. Expert Opin Investig Drugs. 2022;31:59&#x02013;78.<pub-id pub-id-type="pmid">35034511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial</article-title><source>EClinicalMedicine</source><year>2024</year><volume>68</volume><fpage>102415</fpage><pub-id pub-id-type="pmid">38235421</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415.<pub-id pub-id-type="pmid">38235421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>MZ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery</article-title><source>Eur Rev Med Pharm Sci</source><year>2020</year><volume>24</volume><fpage>12929</fpage><lpage>37</lpage></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Li L, Xu MZ, Wang L, Jiang J, Dong LH, Chen F, et al. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharm Sci. 2020;24:12929&#x02013;37.</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The role of MAPK signaling pathway in the Her-2-positive meningiomas</article-title><source>Oncol Rep.</source><year>2016</year><volume>36</volume><fpage>685</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">27279438</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Wang Z, Wang W, Xu S, Wang S, Tu Y, Xiong Y, et al. The role of MAPK signaling pathway in the Her-2-positive meningiomas. Oncol Rep. 2016;36:685&#x02013;95.<pub-id pub-id-type="pmid">27279438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study</article-title><source>Cancer Commun (Lond)</source><year>2021</year><volume>41</volume><fpage>1173</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">34665942</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41:1173&#x02013;82.<pub-id pub-id-type="pmid">34665942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Disitamab Vedotin: First Approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>1929</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">34661865</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81:1929&#x02013;35.<pub-id pub-id-type="pmid">34661865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name></person-group><article-title>Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>334</fpage></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Gong J, Fang J, Shen L. Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer. J Clin Oncol. 2020;38:334.</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>P</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name></person-group><article-title>The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><fpage>3659</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">36245247</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Tarantino P, Tolaney SM. The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors. Cancer Res. 2022;82:3659&#x02013;61.<pub-id pub-id-type="pmid">36245247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name></person-group><article-title>HER2-targeted therapies - a role beyond breast cancer</article-title><source>Nat Rev Clin Oncol</source><year>2020</year><volume>17</volume><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">31548601</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33&#x02013;48.<pub-id pub-id-type="pmid">31548601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Barok</surname><given-names>M</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>K&#x000f6;ninki</surname><given-names>K</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name></person-group><article-title>Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer</article-title><source>Cancer Lett</source><year>2011</year><volume>306</volume><fpage>171</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21458915</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Barok M, Tanner M, K&#x000f6;ninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:171&#x02013;9.<pub-id pub-id-type="pmid">21458915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Thuss-Patience</surname><given-names>PC</given-names></name><name><surname>Shah</surname><given-names>MA</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Castro</surname><given-names>H</given-names></name><etal/></person-group><article-title>Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>640</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">28343975</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640&#x02013;53.<pub-id pub-id-type="pmid">28343975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)</article-title><source>Gastric Cancer</source><year>2019</year><volume>22</volume><fpage>527</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">30386954</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22:527&#x02013;35.<pub-id pub-id-type="pmid">30386954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakada</surname><given-names>T</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Jikoh</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Agatsuma</surname><given-names>T</given-names></name></person-group><article-title>The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy</article-title><source>Chem Pharm Bull (Tokyo)</source><year>2019</year><volume>67</volume><fpage>173</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">30827997</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67:173&#x02013;85.<pub-id pub-id-type="pmid">30827997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation</article-title><source>Mol Cancer Ther</source><year>2024</year><volume>23</volume><fpage>1639</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">39082754</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Yue H, Xu H, Ma L, Li X, Yang B, Wang X, et al. A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation. Mol Cancer Ther. 2024;23:1639&#x02013;51.<pub-id pub-id-type="pmid">39082754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Tong</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)</article-title><source>Eur J Med Chem</source><year>2019</year><volume>183</volume><fpage>111682</fpage><pub-id pub-id-type="pmid">31563805</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.<pub-id pub-id-type="pmid">31563805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>SK</given-names></name><name><surname>Kwon</surname><given-names>WS</given-names></name><name><surname>Jeong</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Yu</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer</article-title><source>Sci Rep.</source><year>2023</year><volume>13</volume><fpage>22648</fpage><pub-id pub-id-type="pmid">38114573</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Park J, Kang SK, Kwon WS, Jeong I, Kim TS, Yu SY, et al. Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. Sci Rep. 2023;13:22648.<pub-id pub-id-type="pmid">38114573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Takegawa</surname><given-names>N</given-names></name><name><surname>Nonagase</surname><given-names>Y</given-names></name><name><surname>Yonesaka</surname><given-names>K</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Maenishi</surname><given-names>O</given-names></name><name><surname>Ogitani</surname><given-names>Y</given-names></name><etal/></person-group><article-title>DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance</article-title><source>Int J Cancer</source><year>2017</year><volume>141</volume><fpage>1682</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28677116</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682&#x02013;9.<pub-id pub-id-type="pmid">28677116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Iwasa</surname><given-names>S</given-names></name><name><surname>Sugimoto</surname><given-names>N</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Sakai</surname><given-names>D</given-names></name><etal/></person-group><article-title>Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer</article-title><source>N. Engl J Med</source><year>2020</year><volume>382</volume><fpage>2419</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">32469182</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl J Med. 2020;382:2419&#x02013;30.<pub-id pub-id-type="pmid">32469182</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Ogitani</surname><given-names>Y</given-names></name><name><surname>Aida</surname><given-names>T</given-names></name><name><surname>Hagihara</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>J</given-names></name><name><surname>Ishii</surname><given-names>C</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><etal/></person-group><article-title>DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>5097</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">27026201</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22:5097&#x02013;108.<pub-id pub-id-type="pmid">27026201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Shimomura</surname><given-names>A</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Yonemori</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>1512</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">29037983</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512&#x02013;22.<pub-id pub-id-type="pmid">29037983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>O'Shaughnessy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer</article-title><source>Clin Cancer Res</source><year>2022</year><volume>28</volume><fpage>4212</fpage><lpage>21</lpage></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Zhang J, Ji D, Shen W, Xiao Q, Gu Y, O'Shaughnessy J, et al. Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer. Clin Cancer Res. 2022;28:4212&#x02013;21.</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Skidmore</surname><given-names>L</given-names></name><name><surname>Sakamuri</surname><given-names>S</given-names></name><name><surname>Knudsen</surname><given-names>NA</given-names></name><name><surname>Hewet</surname><given-names>AG</given-names></name><name><surname>Milutinovic</surname><given-names>S</given-names></name><name><surname>Barkho</surname><given-names>W</given-names></name><etal/></person-group><article-title>ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers</article-title><source>Mol Cancer Ther</source><year>2020</year><volume>19</volume><fpage>1833</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">32669315</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W, et al. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. Mol Cancer Ther. 2020;19:1833&#x02013;43.<pub-id pub-id-type="pmid">32669315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>MZ</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>XL</given-names></name><etal/></person-group><article-title>Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma</article-title><source>Cell Rep. Med</source><year>2022</year><volume>3</volume><fpage>100814</fpage><pub-id pub-id-type="pmid">36384091</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, et al. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep. Med. 2022;3:100814.<pub-id pub-id-type="pmid">36384091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Barok</surname><given-names>M</given-names></name><name><surname>Le Joncour</surname><given-names>V</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Salmikangas</surname><given-names>M</given-names></name><name><surname>Laakkonen</surname><given-names>P</given-names></name><etal/></person-group><article-title>ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer</article-title><source>Cancer Lett</source><year>2020</year><volume>473</volume><fpage>156</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">31904483</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P, et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020;473:156&#x02013;63.<pub-id pub-id-type="pmid">31904483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors</article-title><source>Antib Ther</source><year>2021</year><volume>4</volume><fpage>175</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">34532642</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Li H, Zhang X, Xu Z, Li L, Liu W, Dai Z, et al. Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antib Ther. 2021;4:175&#x02013;84.<pub-id pub-id-type="pmid">34532642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Yun</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name></person-group><article-title>Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers</article-title><source>Front Mol Biosci</source><year>2022</year><volume>9</volume><fpage>847835</fpage><pub-id pub-id-type="pmid">35295841</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9:847835.<pub-id pub-id-type="pmid">35295841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma</article-title><source>Eur J Cancer</source><year>2024</year><volume>205</volume><fpage>114096</fpage><pub-id pub-id-type="pmid">38772302</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Qu W, Fu C, Han W, Luo H, Quan J, Chen L, et al. A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma. Eur J Cancer. 2024;205:114096.<pub-id pub-id-type="pmid">38772302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Ju</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers</article-title><source>Adv Sci (Weinh)</source><year>2021</year><volume>8</volume><fpage>e2102414</fpage><pub-id pub-id-type="pmid">34664433</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Shin SH, Park YH, Park SS, Ju EJ, Park J, Ko EJ, et al. An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers. Adv Sci (Weinh). 2021;8:e2102414.<pub-id pub-id-type="pmid">34664433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Graziani</surname><given-names>EI</given-names></name><name><surname>Sung</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Narayanan</surname><given-names>B</given-names></name><name><surname>Marquette</surname><given-names>K</given-names></name><name><surname>Puthenveetil</surname><given-names>S</given-names></name><etal/></person-group><article-title>PF-06804103, A Site-specific Anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing Breast, Gastric, and Lung Cancers</article-title><source>Mol Cancer Ther</source><year>2020</year><volume>19</volume><fpage>2068</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">32747418</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, et al. PF-06804103, A Site-specific Anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Mol Cancer Ther. 2020;19:2068&#x02013;78.<pub-id pub-id-type="pmid">32747418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>U</given-names></name><name><surname>van Herpen</surname><given-names>CML</given-names></name><name><surname>Saura</surname><given-names>C</given-names></name><name><surname>Thistlethwaite</surname><given-names>F</given-names></name><name><surname>Lord</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><etal/></person-group><article-title>Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><fpage>1124</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">31257177</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124&#x02013;35.<pub-id pub-id-type="pmid">31257177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>R</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study</article-title><source>Cancer Commun (Lond)</source><year>2021</year><volume>41</volume><fpage>171</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">33528890</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, et al. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021;41:171&#x02013;82.<pub-id pub-id-type="pmid">33528890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>DiPeri</surname><given-names>TP</given-names></name><name><surname>Evans</surname><given-names>KW</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Akcakanat</surname><given-names>A</given-names></name><name><surname>Raso</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Co-clinical trial of novel bispecific Anti-HER2 antibody zanidatamab in patient-derived xenografts</article-title><source>Cancer Discov</source><year>2024</year><volume>14</volume><fpage>828</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">38358339</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, et al. Co-clinical trial of novel bispecific Anti-HER2 antibody zanidatamab in patient-derived xenografts. Cancer Discov. 2024;14:828&#x02013;45.<pub-id pub-id-type="pmid">38358339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>SA</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name></person-group><article-title>Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>1543</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">29563144</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018;67:1543&#x02013;52.<pub-id pub-id-type="pmid">29563144</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Uranga</surname><given-names>JA</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Abalo</surname><given-names>R</given-names></name></person-group><article-title>Guanylate cyclase C: a current hot target, from physiology to pathology</article-title><source>Curr Med Chem</source><year>2018</year><volume>25</volume><fpage>1879</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">29210639</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Uranga JA, Castro M, Abalo R. Guanylate cyclase C: a current hot target, from physiology to pathology. Curr Med Chem. 2018;25:1879&#x02013;908.<pub-id pub-id-type="pmid">29210639</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>H</given-names></name><name><surname>Mathew</surname><given-names>JKK</given-names></name><name><surname>Visweswariah</surname><given-names>SS</given-names></name></person-group><article-title>Receptor guanylyl cyclase C and cyclic GMP in health and disease: perspectives and therapeutic opportunities</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>911459</fpage><pub-id pub-id-type="pmid">35846281</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Prasad H, Mathew JKK, Visweswariah SS. Receptor guanylyl cyclase C and cyclic GMP in health and disease: perspectives and therapeutic opportunities. Front Endocrinol (Lausanne). 2022;13:911459.<pub-id pub-id-type="pmid">35846281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Bolleddula</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Shadid</surname><given-names>M</given-names></name><name><surname>Kamali</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Chowdhury</surname><given-names>SK</given-names></name></person-group><article-title>Pharmacokinetics and catabolism of [(3)H]TAK-164, a guanylyl cyclase C targeted antibody-drug conjugate</article-title><source>Drug Metab Dispos</source><year>2020</year><volume>48</volume><fpage>1239</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">32843329</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Bolleddula J, Shah A, Shadid M, Kamali A, Smith MD, Chowdhury SK. Pharmacokinetics and catabolism of [(3)H]TAK-164, a guanylyl cyclase C targeted antibody-drug conjugate. Drug Metab Dispos. 2020;48:1239&#x02013;45.<pub-id pub-id-type="pmid">32843329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Yousif</surname><given-names>AO</given-names></name><name><surname>Cvet</surname><given-names>D</given-names></name><name><surname>Gallery</surname><given-names>M</given-names></name><name><surname>Bannerman</surname><given-names>BM</given-names></name><name><surname>Ganno</surname><given-names>ML</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Preclinical antitumor activity and biodistribution of a novel anti-GCC antibody-drug conjugate in patient-derived xenografts</article-title><source>Mol Cancer Ther</source><year>2020</year><volume>19</volume><fpage>2079</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">32788205</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Abu-Yousif AO, Cvet D, Gallery M, Bannerman BM, Ganno ML, Smith MD, et al. Preclinical antitumor activity and biodistribution of a novel anti-GCC antibody-drug conjugate in patient-derived xenografts. Mol Cancer Ther. 2020;19:2079&#x02013;88.<pub-id pub-id-type="pmid">32788205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>B</given-names></name><name><surname>Khera</surname><given-names>E</given-names></name><name><surname>Calopiz</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Ganno</surname><given-names>ML</given-names></name><name><surname>Cilliers</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of TAK-164 antibody drug conjugate coadministered with unconjugated antibody</article-title><source>Aaps j</source><year>2022</year><volume>24</volume><fpage>107</fpage><pub-id pub-id-type="pmid">36207468</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Menezes B, Khera E, Calopiz M, Smith MD, Ganno ML, Cilliers C, et al. Pharmacokinetics and pharmacodynamics of TAK-164 antibody drug conjugate coadministered with unconjugated antibody. Aaps j. 2022;24:107.<pub-id pub-id-type="pmid">36207468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Leal</surname><given-names>AD</given-names></name><name><surname>Parikh</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Bahamon</surname><given-names>B</given-names></name><etal/></person-group><article-title>A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C</article-title><source>Cancer Chemother Pharm</source><year>2023</year><volume>91</volume><fpage>291</fpage><lpage>300</lpage></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Kim R, Leal AD, Parikh A, Ryan DP, Wang S, Bahamon B, et al. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharm. 2023;91:291&#x02013;300.</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Almhanna</surname><given-names>K</given-names></name><name><surname>Prithviraj</surname><given-names>GK</given-names></name><name><surname>Veiby</surname><given-names>P</given-names></name><name><surname>Kalebic</surname><given-names>T</given-names></name></person-group><article-title>Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies</article-title><source>Pharm Ther</source><year>2017</year><volume>170</volume><fpage>8</fpage><lpage>13</lpage></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Almhanna K, Prithviraj GK, Veiby P, Kalebic T. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. Pharm Ther. 2017;170:8&#x02013;13.</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Almhanna</surname><given-names>K</given-names></name><name><surname>Kalebic</surname><given-names>T</given-names></name><name><surname>Cruz</surname><given-names>C</given-names></name><name><surname>Faris</surname><given-names>JE</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>5049</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">27178743</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, et al. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res. 2016;22:5049&#x02013;57.<pub-id pub-id-type="pmid">27178743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Fasanmade</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Danaee</surname><given-names>H</given-names></name><etal/></person-group><article-title>TAK-264 (MLN0264) in previously treated asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study</article-title><source>Cancer Res Treat</source><year>2018</year><volume>50</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">28494535</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, et al. TAK-264 (MLN0264) in previously treated asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study. Cancer Res Treat. 2018;50:398&#x02013;404.<pub-id pub-id-type="pmid">28494535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Capone</surname><given-names>E</given-names></name><name><surname>Lattanzio</surname><given-names>R</given-names></name><name><surname>Gasparri</surname><given-names>F</given-names></name><name><surname>Orsini</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Iacobelli</surname><given-names>V</given-names></name><etal/></person-group><article-title>EV20/NMS-P945, a novel thienoindole based antibody-drug conjugate targeting HER-3 for solid tumors</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>483.</fpage><pub-id pub-id-type="pmid">33918158</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, et al. EV20/NMS-P945, a novel thienoindole based antibody-drug conjugate targeting HER-3 for solid tumors. Pharmaceutics. 2021;13:483.<pub-id pub-id-type="pmid">33918158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Janne</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Steuer</surname><given-names>C</given-names></name><name><surname>Vigliotti</surname><given-names>M</given-names></name><name><surname>Iacobucci</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>9010</fpage></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Janne P, Yu H, Johnson M, Steuer C, Vigliotti M, Iacobucci C, et al. Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 2019;37:9010.</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Urano</surname><given-names>Y</given-names></name><name><surname>Sakabe</surname><given-names>M</given-names></name><name><surname>Kosaka</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Mitsunaga</surname><given-names>M</given-names></name><name><surname>Asanuma</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rapid cancer detection by topically spraying a &#x003b3;-glutamyltranspeptidase-activated fluorescent probe</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>110ra9</fpage></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Urano Y, Sakabe M, Kosaka N, Ogawa M, Mitsunaga M, Asanuma D, et al. Rapid cancer detection by topically spraying a &#x003b3;-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med. 2011;3:110ra9.</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Haratani</surname><given-names>K</given-names></name><name><surname>Yonesaka</surname><given-names>K</given-names></name><name><surname>Takamura</surname><given-names>S</given-names></name><name><surname>Maenishi</surname><given-names>O</given-names></name><name><surname>Kato</surname><given-names>R</given-names></name><name><surname>Takegawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>374</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">31661465</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020;130:374&#x02013;88.<pub-id pub-id-type="pmid">31661465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Steuer</surname><given-names>CE</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>W-C</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Kim</surname><given-names>D-W</given-names></name><etal/></person-group><article-title>Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><fpage>9017</fpage></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Steuer CE, Hayashi H, Su W-C, Nishio M, Johnson ML, Kim D-W, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. J Clin Oncol. 2022;40:9017.</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Kogawa</surname><given-names>T</given-names></name><name><surname>Yonemori</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name><etal/></person-group><article-title>Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>2512</fpage></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Kogawa T, Yonemori K, Masuda N, Takahashi S, Takahashi M, Iwase H, et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. J Clin Oncol. 2018;36:2512.</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Yonemori</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Kogawa</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><fpage>iii48</fpage></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Yonemori K, Masuda N, Takahashi S, Kogawa T, Nakayama T, Yamamoto Y, et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial. Ann Oncol. 2019;30:iii48.</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzanne</surname><given-names>R</given-names></name></person-group><article-title>MCLA-128 fights NRG1 fusion-positive cancers</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><fpage>1636.</fpage></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Suzanne R. MCLA-128 fights NRG1 fusion-positive cancers. Cancer Discov. 2019;9:1636.</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lyu</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><etal/></person-group><article-title>Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer</article-title><source>Breast Cancer Res</source><year>2013</year><volume>15</volume><fpage>R101</fpage><pub-id pub-id-type="pmid">24168763</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, et al. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res. 2013;15:R101.<pub-id pub-id-type="pmid">24168763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname><given-names>D</given-names></name><name><surname>Ligon</surname><given-names>GF</given-names></name><name><surname>Lillquist</surname><given-names>JS</given-names></name><name><surname>Seibel</surname><given-names>SB</given-names></name><name><surname>Wallweber</surname><given-names>G</given-names></name><name><surname>Neumeister</surname><given-names>VM</given-names></name><etal/></person-group><article-title>ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0181356</fpage><pub-id pub-id-type="pmid">28723928</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Alvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, et al. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. PLoS One. 2017;12:e0181356.<pub-id pub-id-type="pmid">28723928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukita</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Katsuno</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>Tight junction-based epithelial microenvironment and cell proliferation</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>6930</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19029935</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Tsukita S, Yamazaki Y, Katsuno T, Tamura A, Tsukita S. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene. 2008;27:6930&#x02013;8.<pub-id pub-id-type="pmid">19029935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>T&#x000fc;reci</surname><given-names>&#x000d6;</given-names></name><name><surname>Manikhas</surname><given-names>G</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Rusyn</surname><given-names>A</given-names></name><name><surname>Vynnychenko</surname><given-names>I</given-names></name><etal/></person-group><article-title>FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>609</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">33610734</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Sahin U, T&#x000fc;reci &#x000d6;, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609&#x02013;19.<pub-id pub-id-type="pmid">33610734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Shibahara</surname><given-names>J</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><name><surname>Shinozaki</surname><given-names>A</given-names></name><name><surname>Umeda</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Claudin-18 is an early-stage marker of pancreatic carcinogenesis</article-title><source>J Histochem Cytochem</source><year>2011</year><volume>59</volume><fpage>942</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21832145</pub-id>
</element-citation><mixed-citation id="mc-CR160" publication-type="journal">Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59:942&#x02013;52.<pub-id pub-id-type="pmid">21832145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Toom</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><fpage>105</fpage><pub-id pub-id-type="pmid">28494772</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105.<pub-id pub-id-type="pmid">28494772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors</article-title><source>Cell Rep. Med</source><year>2024</year><volume>5</volume><fpage>101710</fpage><pub-id pub-id-type="pmid">39232496</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Xu G, Liu W, Wang Y, Wei X, Liu F, He Y, et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep. Med. 2024;5:101710.<pub-id pub-id-type="pmid">39232496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>DY</given-names></name><name><surname>Liu</surname><given-names>FR</given-names></name><name><surname>Wei</surname><given-names>XL</given-names></name><name><surname>Luo</surname><given-names>SX</given-names></name><name><surname>Zhuang</surname><given-names>ZX</given-names></name><name><surname>Wang</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial</article-title><source>Lancet Oncol</source><year>2025</year><volume>26</volume><fpage>227</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">39788133</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227&#x02013;38.<pub-id pub-id-type="pmid">39788133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>DM</given-names></name><name><surname>Sharkey</surname><given-names>RM</given-names></name></person-group><article-title>Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan</article-title><source>MAbs</source><year>2019</year><volume>11</volume><fpage>987</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">31208270</pub-id>
</element-citation><mixed-citation id="mc-CR164" publication-type="journal">Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987&#x02013;95.<pub-id pub-id-type="pmid">31208270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>951589</fpage><pub-id pub-id-type="pmid">36620535</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2022;12:951589.<pub-id pub-id-type="pmid">36620535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Cardillo</surname><given-names>TM</given-names></name><name><surname>Govindan</surname><given-names>SV</given-names></name><name><surname>Sharkey</surname><given-names>RM</given-names></name><name><surname>Trisal</surname><given-names>P</given-names></name><name><surname>Arrojo</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers</article-title><source>Bioconjug Chem</source><year>2015</year><volume>26</volume><fpage>919</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">25915780</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015;26:919&#x02013;31.<pub-id pub-id-type="pmid">25915780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Challita-Eid</surname><given-names>PM</given-names></name><name><surname>Satpayev</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>An</surname><given-names>Z</given-names></name><name><surname>Morrison</surname><given-names>K</given-names></name><name><surname>Shostak</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>3003</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">27013195</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76:3003&#x02013;13.<pub-id pub-id-type="pmid">27013195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-&#x003ba;B signaling by down-regulation of miR-520c-3p</article-title><source>Cancer Cell Int</source><year>2022</year><volume>22</volume><fpage>252</fpage><pub-id pub-id-type="pmid">35953862</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Liu Y, Li G, Zhang Y, Li L, Zhang Y, Huang X, et al. Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-&#x003ba;B signaling by down-regulation of miR-520c-3p. Cancer Cell Int. 2022;22:252.<pub-id pub-id-type="pmid">35953862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Siddharth</surname><given-names>S</given-names></name><name><surname>Goutam</surname><given-names>K</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Nayak</surname><given-names>A</given-names></name><name><surname>Nayak</surname><given-names>D</given-names></name><name><surname>Sethy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nectin-4 is a breast cancer stem cell marker that induces WNT/&#x003b2;-catenin signaling via Pi3k/Akt axis</article-title><source>Int J Biochem Cell Biol</source><year>2017</year><volume>89</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">28600142</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Siddharth S, Goutam K, Das S, Nayak A, Nayak D, Sethy C, et al. Nectin-4 is a breast cancer stem cell marker that induces WNT/&#x003b2;-catenin signaling via Pi3k/Akt axis. Int J Biochem Cell Biol. 2017;89:85&#x02013;94.<pub-id pub-id-type="pmid">28600142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>PC</given-names></name><name><surname>Boylan</surname><given-names>KLM</given-names></name><name><surname>Walcheck</surname><given-names>B</given-names></name><name><surname>Heinze</surname><given-names>R</given-names></name><name><surname>Geller</surname><given-names>MA</given-names></name><name><surname>Argenta</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><fpage>6339</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28232483</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292:6339&#x02013;51.<pub-id pub-id-type="pmid">28232483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer</article-title><source>Oncol Lett</source><year>2018</year><volume>15</volume><fpage>8789</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">29805618</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Zhang Y, Zhang J, Shen Q, Yin W, Huang H, Liu Y, et al. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15:8789&#x02013;95.<pub-id pub-id-type="pmid">29805618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Ni</surname><given-names>Q</given-names></name></person-group><article-title>Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway</article-title><source>Hum Pathol</source><year>2018</year><volume>72</volume><fpage>107</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">29208564</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Zhang Y, Chen P, Yin W, Ji Y, Shen Q, Ni Q. Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol. 2018;72:107&#x02013;16.<pub-id pub-id-type="pmid">29208564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Gai</surname><given-names>J</given-names></name><etal/></person-group><article-title>A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer</article-title><source>J Nanobiotechnology</source><year>2024</year><volume>22</volume><fpage>256</fpage><pub-id pub-id-type="pmid">38755613</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Wu Y, Zhu M, Sun B, Chen Y, Huang Y, Gai J, et al. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer. J Nanobiotechnology. 2024;22:256.<pub-id pub-id-type="pmid">38755613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Iwasa</surname><given-names>S</given-names></name><name><surname>Sugimoto</surname><given-names>N</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Sakai</surname><given-names>D</given-names></name><etal/></person-group><article-title>Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>816</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">36379002</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41:816&#x02013;25.<pub-id pub-id-type="pmid">36379002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>di Bartolomeo</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>E</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><etal/></person-group><article-title>Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><fpage>744</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">37329891</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744&#x02013;56.<pub-id pub-id-type="pmid">37329891</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>